

# COVID-19 mRNA VACCINE

## RISK MANAGEMENT PLAN (RMP)

For a summary of the RMP, please refer to [PART VI](#).

## COVID-19 mRNA VACCINE RISK MANAGEMENT PLAN

RMP Version number: 1.0

Data lock point for this RMP: 17 December 2020

Date of final sign off: 21 December 2020

Rationale for submitting an updated RMP: Responses to the PRAC Rolling Review Management Plan Updated Assessment Report received on 18 December 2020.

Summary of significant changes in this RMP:

RMP Part/Module	Major Change (s)
<b>PART I. PRODUCT(S) OVERVIEW</b>	No changes made.
<b>PART II. SAFETY SPECIFICATION</b>	
<b>Module SI.</b> Epidemiology of the Indication(s) and Target Populations	Minor change.
<b>Module SII.</b> Non-Clinical Part of the Safety Specification	Minor change.
<b>Module SIII.</b> Clinical Trial Exposure	No changes made.
<b>Module SIV.</b> Populations Not Studied in Clinical Trials	Text in Table 16 updated for use in pregnant and breastfeeding women.
<b>Module SV.</b> Post-Authorisation Experience	Minor change.
<b>Module SVI.</b> Additional EU Requirements for the Safety Specification	No changes made.
<b>Module SVII.</b> Identified and Potential Risks	<p>- The list of safety concerns has been updated:</p> <ul style="list-style-type: none"> <li>• Added Important Identified Risk (Anaphylaxis)</li> <li>• Added Missing information [Use in immunocompromised patients; Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders); Use in patients with autoimmune or inflammatory disorders]</li> <li>• Renamed Missing information (from “Use in pregnancy” to “Use in pregnancy and while breast feeding”).</li> </ul>

RMP Part/Module	Major Change (s)
<p><b>Module SVIII.</b> Summary of the Safety Concerns</p>	<p>- The list of safety concerns has been updated:</p> <ul style="list-style-type: none"> <li>• Added Important Identified Risk (Anaphylaxis)</li> <li>• Added Missing information [Use in immunocompromised patients; Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders); Use in patients with autoimmune or inflammatory disorders]</li> <li>• Renamed Missing information (from “Use in pregnancy” to “Use in pregnancy and while breast feeding”)</li> </ul>
<p><b>PART III.</b> PHARMACOVIGILANCE PLAN (INCLUDING POST AUTHORISATION SAFETY STUDIES)</p>	<p><i>PART III.1 Routine Pharmacovigilance Activities</i></p> <ul style="list-style-type: none"> <li>- Monthly summary safety reports text has been updated to meet the request about Bell’s palsy.</li> <li>- Text related to frequency of analyses of adverse event and product complaint has been updated to meet the request.</li> </ul> <p><i>PART III.2 Additional Pharmacovigilance Activities</i></p> <ul style="list-style-type: none"> <li>- List of studies has been updated to address the safety concerns.</li> </ul> <p><i>PART III.3. Summary Table of Additional Pharmacovigilance Activities</i></p> <ul style="list-style-type: none"> <li>- List of studies has been updated to address the safety concerns.</li> </ul>
<p><b>PART IV.</b> PLANS FOR POST AUTHORISATION EFFICACY STUDIES</p>	<p>No changes made.</p>
<p><b>PART V.</b> RISK MINIMISATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMISATION ACTIVITIES)</p>	<p><i>PART V.1. Routine Risk Minimisation Measures</i></p> <ul style="list-style-type: none"> <li>- Routine Risk Minimisation Measures updated for the safety concerns.</li> </ul> <p><i>PART V.3. Summary of Risk Minimisation Measures</i></p> <ul style="list-style-type: none"> <li>- Summary of Risk Minimisation Measures updated for the new safety concerns added.</li> <li>- New studies added for addressing the safety concern Anaphylaxis.</li> </ul>
<p><b>PART VI.</b> SUMMARY OF THE RISK MANAGEMENT PLAN</p>	<p><i>PART VI. IIA List of Important Risks and Missing Information</i></p> <ul style="list-style-type: none"> <li>- The list of safety concerns has been updated:</li> <li>• Added Important Identified Risk (Anaphylaxis)</li> <li>• Added Missing information [Use in immunocompromised patients; Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders); Use in patients with autoimmune or inflammatory disorders]</li> <li>• Renamed Missing information (from “Use in pregnancy” to “Use in pregnancy and while breast feeding”)</li> </ul> <p><i>PART VI. IIB Summary of Important Risks</i></p> <ul style="list-style-type: none"> <li>- The list of safety concerns has been updated:</li> <li>• Added Important Identified Risk (Anaphylaxis)</li> <li>• Added Missing information [Use in immunocompromised patients; Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders); Use in patients with autoimmune or inflammatory disorders]</li> </ul>

RMP Part/Module	Major Change (s)
<p><b>PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN</b> (cont'd)</p>	<ul style="list-style-type: none"> <li>• Renamed Missing information (from “Use in pregnancy” to “Use in pregnancy and while breast feeding”)</li> </ul> <p>PART VI. II.C.1 Studies which are Conditions of the Marketing Authorisation</p> <ul style="list-style-type: none"> <li>- Study C4591001 moved from PART VI. II.C.2 to this section.</li> </ul> <p>PART VI. II.C.2 Other Studies in Post-Authorisation Development Plan:</p> <ul style="list-style-type: none"> <li>- Study C4591001 moved from this section to PART VI. II.C.1.</li> </ul>
<p><b>PART VII. ANNEXES TO THE RISK MANAGEMENT PLAN</b></p>	<p>Annex 2:</p> <ul style="list-style-type: none"> <li>- List of studies has been updated to address the new safety concerns.</li> <li>- New studies added for addressing the safety concern Anaphylaxis.</li> </ul> <p>Annex 7 updated to include Traceability and Vaccination Reminder Card</p> <p>Annex 8:</p> <ul style="list-style-type: none"> <li>- Changes respect version 0.3 added.</li> </ul>

Other RMP versions under evaluation:

None

QPPV name<sup>1</sup>: Barbara De Bernardi

QPPV oversight declaration: The content of this RMP has been reviewed and approved by the marketing authorisation applicant’s QPPV. The electronic signature is available on file.

---

<sup>1</sup> QPPV name will not be redacted in case of an access to documents request; see HMA/EMA Guidance document on the identification of commercially confidential information and personal data within the structure of the marketing-authorisation application; available on EMA website <http://www.ema.europa.eu>

## LIST OF ABBREVIATIONS

<b>Abbreviation</b>	<b>Definition of Term</b>
AE	adverse event
AESI	Adverse event of special interest
A:G	albumin:globulin
BMI	body mass index
COVID-19	coronavirus disease 2019
CSR	clinical study report
CT	clinical trial
DART	developmental and reproductive toxicology
DCA	data capture aid
DLP	data-lock point
ECDC	European Center for Disease Control
ED	emergency department
EEA	European Economic Area
EHR	electronic health records
EMA	European Medicines Agency
EUA	emergency use authorization
EU	European Union
FDA	(US) Food and Drug Administration
GLP	good laboratory practice
HBV	hepatitis b virus
HCV	hepatitis c virus
HIV	human immunodeficiency virus
IA	interim analysis
ICU	intensive care unit
IFN	interferon
IM	intramuscular(ly)
IND	investigational new drug
LNP	lipid nanoparticle
LoQ	List of questions
MAA	marketing authorization applicant
MedDRA	Medical Dictionary for Regulatory Activities
mRNA	messenger ribonucleic acid
NDA	new drug application
NHP	nonhuman primate
PC	product complaint
PK	pharmacokinetic
RA	rheumatoid arthritis
RBC	red blood cell
RMP	risk management plan
RNA	ribonucleic acid
SAE	serious adverse event
SARS	severe acute respiratory syndrome

<b>Abbreviation</b>	<b>Definition of Term</b>
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
siRNA	small-interfering RNA
SmPC	summary of product characteristics
SPEAC	Safety Platform for Emergency vACcines
TESSy	The European Surveillance System
T <sub>H</sub> 2	T helper cell type 2
TME	targeted medical event
UK	United Kingdom
US	United States
V8	variant 8
V9	variant 9
VAC4EU	Vaccine monitoring Collaboration for Europe
VAED	vaccine-associated enhanced disease
VAERD	vaccine-associated enhanced respiratory disease
WBC	white blood cells
WHO	World Health Organization
WOCBP	women of child-bearing potential

## TABLE OF CONTENTS

LIST OF ABBREVIATIONS.....	4
LIST OF TABLES.....	8
LIST OF FIGURES.....	9
PART I. PRODUCT(S) OVERVIEW.....	10
PART II. SAFETY SPECIFICATION.....	12
Module SI. Epidemiology of the Indication(s) and Target Population (s).....	12
Module SII. Non-Clinical Part of the Safety Specification.....	17
Module SIII. Clinical Trial Exposure.....	20
Module SIV. Populations Not Studied in Clinical Trials.....	57
SIV.1. Exclusion Criteria in Pivotal Clinical Studies Within the Development Programme.....	57
SIV.2. Limitations to Detect Adverse Reactions in Clinical Trial Development Programmes.....	59
SIV.3. Limitations in Respect to Populations Typically Under-Represented in Clinical Trial Development Programmes.....	59
Module SV. Post-Authorisation Experience.....	60
SV.1. Post-Authorisation Exposure.....	60
SV.1.1. Method Used to Calculate Exposure.....	61
SV.1.2. Exposure.....	61
Module SVI. Additional EU Requirements for the Safety Specification.....	62
Module SVII. Identified and Potential Risks.....	62
SVII.1. Identification of Safety Concerns in the Initial RMP Submission.....	62
SVII.1.1. Risks not Considered Important for Inclusion in the List of Safety Concerns in the RMP.....	63
SVII.1.2. Risks Considered Important for Inclusion in the List of Safety Concerns in the RMP.....	66
SVII.2. New Safety Concerns and Reclassification with a Submission of an Updated RMP.....	68
SVII.3. Details of Important Identified Risks, Important Potential Risks, and Missing Information.....	68
SVII.3.1. Presentation of Important Identified Risks and Important Potential Risks.....	68
SVII.3.2. Presentation of the Missing Information.....	70
Module SVIII. Summary of the Safety Concerns.....	73

PART III. PHARMACOVIGILANCE PLAN (INCLUDING POST-AUTHORISATION SAFETY STUDIES) .....	74
III.1. Routine Pharmacovigilance Activities .....	74
III.2. Additional Pharmacovigilance Activities.....	79
III.3. Summary Table of Additional Pharmacovigilance Activities.....	87
III.3.1. On-Going and Planned Additional Pharmacovigilance Activities .....	87
PART IV. PLANS FOR POST AUTHORISATION EFFICACY STUDIES .....	91
PART V. RISK MINIMISATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMISATION ACTIVITIES).....	92
V.1. Routine Risk Minimisation Measures .....	92
V.2. Additional Risk Minimisation Measures Risk Minimisation Measures .....	94
V.3. Summary of Risk Minimisation Measures .....	94
PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN .....	97
I. The Medicine and What It Is Used For.....	97
II. Risks Associated With the Medicine and Activities to Minimise or Further Characterise the Risks .....	97
II.A List of Important Risks and Missing Information.....	98
II.B Summary of Important Risks .....	98
II.C Post-Authorisation Development Plan .....	102
II.C.1 Studies which are Conditions of the Marketing Authorisation .....	102
II.C.2 Other Studies in Post-Authorisation Development Plan.....	102
PART VII. ANNEXES TO THE RISK MANAGEMENT PLAN.....	103
REFERENCES .....	104



**LIST OF TABLES**

Table 1.	Distribution and Estimated Cumulative Incidence of Reported Laboratory-Confirmed COVID-19 Cases, by Gender and Age Group — United States, 22 January – 30 May 2020 .....	14
Table 2.	Preconditions among COVID-19 Patients in EU/EEA and UK, by Severity of Disease. Case-based Data from TESSy Produced on 24 September 2020 .....	16
Table 3.	Key Safety Findings and Relevance to Human Usage .....	19
Table 4.	Exposure to BNT162b2 by Age Group and Dose (C4591001) .....	22
Table 5.	Exposure to BNT162b2 by Age Group and Dose (BNT162-01) .....	24
Table 6.	Exposure to BNT162b2 by Age Group and Dose – Children and Elderly Subjects (C4591001).....	27
Table 7.	Exposure to BNT162b2 by Dose (Totals) (C4591001).....	28
Table 8.	Exposure to BNT162b2 by Dose (Totals) (BNT162-01) .....	29
Table 9.	Exposure to BNT162b2 by Dose, Age Group, and Gender (C4591001) .....	31
Table 10.	Exposure to BNT162b2 by Dose, Age Group, and Gender (BNT162-01).....	32
Table 11.	Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (C4591001) .....	34
Table 12.	Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01).....	38
Table 13.	Exposure to BNT162b2 by Dose and Race/Ethnic Origin (C4591001) .....	48
Table 14.	Exposure to BNT162b2 by Dose and Race/Ethnic Origin (BNT162-01) .....	50
Table 15.	Exposure to BNT162b2 (30 µg) by Special Population (C4591001) .....	55
Table 16.	Exposure of Special Populations included or not in Clinical Trial Development Programmes.....	59
Table 17.	Summary of Safety Concerns .....	62
Table 18.	Anaphylaxis .....	68
Table 19.	Vaccine-Associated Enhanced Disease (VAED), including Vaccine-Associated Enhanced Respiratory Disease (VAERD).....	69
Table 20.	Use in pregnancy and while breast feeding .....	70
Table 21.	Use in immunocompromised patients.....	71
Table 22.	Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders) .....	71
Table 23.	Use in patients with autoimmune or inflammatory disorders .....	71
Table 24.	Interaction with other vaccines .....	71

Table 25.	Long term safety data.....	72
Table 26.	Summary of Safety Concerns .....	73
Table 27.	Additional Pharmacovigilance Activities .....	82
Table 28.	On-going and Planned Additional Pharmacovigilance Activities .....	87
Table 29.	Description of Routine Risk Minimisation Measures by Safety Concern.....	92
Table 30.	Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern .....	94
Table 31.	List of Important Risks and Missing Information.....	98
Table 32.	Important Identified Risk: Anaphylaxis.....	98
Table 33.	Important Potential Risk: Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD) .....	99
Table 34.	Missing Information: Use in pregnancy and while breast feeding .....	100
Table 35.	Missing Information: Use in immunocompromised patients.....	100
Table 36.	Missing Information: Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders).....	100
Table 37.	Missing Information: Use in patients with autoimmune or inflammatory disorders.....	101
Table 38.	Missing Information: Interaction with other vaccines .....	101
Table 39.	Missing Information: Long term safety data .....	101

### LIST OF FIGURES

Figure 1.	Age-Gender distribution of COVID-19 Cases as Different Levels of Severity, EU/EEA and UK. Case-based Data from TESSy produced on 07 August 2020 <sup>a</sup> .....	13
-----------	--	----

## PART I. PRODUCT(S) OVERVIEW

<b>Active substance(s) (INN or common name)</b>	COVID-19 mRNA Vaccine is single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free <i>in vitro</i> transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2.
<b>Pharmacotherapeutic group(s) (ATC Code)</b>	Not yet assigned
<b>Marketing Authorisation Applicant</b>	BioNTech Manufacturing GmbH
<b>Medicinal products to which this RMP refers</b>	1
<b>Invented name(s) in the European Economic Area (EEA)</b>	Comirnaty
<b>Marketing authorisation procedure</b>	Centralised
<b>Brief description of the product:</b>	<u>Chemical class</u> Nucleoside-modified messenger RNA is formulated in LNP
	<u>Summary of mode of action</u> The nucleoside-modified messenger RNA in Comirnaty is formulated in LNPs, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19.
	<u>Important information about its composition</u> The COVID-19 mRNA Vaccine: <ul style="list-style-type: none"> <li>– is nucleoside-modified messenger RNA formulated in LNPs;</li> <li>– is a white to off-white frozen dispersion (pH:6.9 – 7.9).</li> <li>– Excipients: <ul style="list-style-type: none"> <li>• ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)</li> <li>• 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)</li> <li>• 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)</li> <li>• cholesterol,</li> <li>• potassium chloride,</li> <li>• potassium dihydrogen phosphate,</li> <li>• sodium chloride,</li> <li>• disodium phosphate dihydrate,</li> <li>• sucrose,</li> <li>• water for injections.</li> </ul> </li> </ul>
<b>Hyperlink to the Product Information:</b>	Please refer to <a href="#">Module 1.3.1</a> of this submission
<b>Indication in the EEA</b>	<u>Proposed:</u> Active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older.

<b>Dosage in the EEA</b>	<u>Proposed:</u> Administered intramuscularly after dilution as a course of 2 doses (0.3 mL each) at least 21 days apart.
<b>Pharmaceutical form and strengths</b>	<u>Proposed:</u> Concentrate dispersion for injection. After dilution each vial contains 5 doses of 0.3 mL
<b>Is/will the product be subject to additional monitoring in the EU?</b>	Yes

## **PART II. SAFETY SPECIFICATION**

### **Module SI. Epidemiology of the Indication(s) and Target Population (s)**

#### **Indication**

Active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older.

#### **Incidence:**

The COVID-19 is caused by a novel coronavirus labelled as SARS-CoV-2. The disease first emerged in December 2019, when a cluster of patients with pneumonia of unknown cause was recognized in Wuhan City, Hubei Province, China.<sup>1</sup> The number of infected cases rapidly increased and spread beyond China throughout the world. On 30 January 2020, the WHO declared COVID-19 a Public Health Emergency of International Concern and thus a pandemic.<sup>2</sup>

Estimates of SARS-CoV-2 incidence change rapidly. As of 9 November 2020, the overall number of people who had been infected with SARS-CoV-2 was over 50 million worldwide. In the EU and the UK, the number of confirmed cases had accumulated to over 9 million people, corresponding to 337 per 100,000 people. Across countries in the EU, the number of confirmed cases ranged from 40 to 1,017 cases per 100,000 people. Slovakia, Greece and Hungary reported an incidence below 50 per 100,000 whereas Spain, Sweden and Luxembourg reported over 700 confirmed cases per 100,000 people.

In the US, the number of confirmed cases had reached over 10 million cases (3,126 per 100,000 people) by the beginning of November 2020. The reported numbers refer only to cases that have been tested and confirmed to be carrying the virus. There are large geographic variations in the proportion of the population tested as well as varied quality of reporting across countries. People who carry the virus but remain asymptomatic are less likely to be tested and therefore mild cases are likely underreported. The numbers should therefore be interpreted with caution.<sup>3</sup>

#### **Prevalence:**

The prevalence of SARS-CoV-2 infection is defined as active cases per 100,000 people including confirmed cases in people who have not recovered or died. On 9 November 2020, the overall prevalence for EU countries was 37.0 active cases per 100,000. The range of reported prevalence was 2.8 to 337.7 per 100,000 with Finland, Estonia and Hungary at the low end and Portugal, Luxembourg and Belgium at the high end.

In the US, the prevalence on the same date was similar to the EU estimates, with 31.5 active cases per 100,000.<sup>3</sup>


**Demographics of the population in the proposed indication and risk factors for the disease:**

While anyone can become infected with SARS-CoV-2, symptoms of COVID-19 can range from very mild (or no symptoms) to severe. Risk factors for developing severe disease, include age over 60 years, male gender, diabetes, severe obesity, chronic kidney disease and congestive heart failure.<sup>4,5,6,7</sup>

The ECDC has since the beginning of the pandemic continuously collected COVID-19 information from all countries who are members of EU/EEA and the UK. In their database TESSy COVID-19 case-based data, including age and gender, are available for approximately 40% of the official number of cases reported by ECDC epidemic intelligence.<sup>8</sup> All countries included in EU/EEA and UK, except Spain, Slovenia and Liechtenstein, have at some point during the pandemic provided case-based data to TESSy, enabling estimates of age and gender distribution representative of the European population.

According to TESSy case-based data, accessed 7 August 2020, (Figure 1), the gender distribution of persons testing positive for SARS-Cov-2 in the European population is similar for most age groups. However, males and older age groups are over-represented among the more severe cases (defined as hospitalized, severe, or fatal). Few cases were reported in people aged younger than 20 years. This data reflects the age distribution of people who met the requirements for being tested and is unlikely to reflect the actual distribution of infections in the population.<sup>8</sup> The distribution of age was different in the period of January-May compared to June-July. Between January and May 2020, 40% of cases were  $\geq 60$  years old and the largest proportion (18.7%) of cases were reported in the 50-59 years age group. In contrast, between June and July, persons aged  $\geq 60$  years accounted for 17.3% of cases and the largest proportion (19.5%) of cases were reported in the 20-29-year age group.<sup>9</sup>

**Figure 1. Age-Gender distribution of COVID-19 Cases as Different Levels of Severity, EU/EEA and UK. Case-based Data from TESSy produced on 07 August 2020 <sup>a</sup>**



Note: "mild"= a case that has not been reported as hospitalized or a case that resulted in death.

a. Data from ECDC. COVID-19 Surveillance report. Week 31, 2020. 7 August 2020. "2.2 Age-sex pyramids".<sup>10</sup>

In the US, surveillance data collected between 22 January 2020 and 30 May 2020 showed a similar age distribution of infected cases in both genders (Table 1). Among 1,320,488 laboratory-confirmed COVID-19 cases, overall incidence per 100,000 persons was higher among individuals aged 40 - 49 years (541.6) and 50 - 59 years (550.5) than among those aged 60 - 69 years (478.4) and 70 - 79 years (464.2). Estimates were highest among persons aged  $\geq 80$  years (902.0) and lowest among children aged  $\leq 9$  years (51.1).<sup>11</sup> During June-August, the COVID-19 pandemic in the US affected a larger proportion of younger persons than during January–May 2020. In this period, incidence was highest in persons aged 20-29 years, accounting for >20% of all confirmed cases. The shift toward younger ages occurred in all four US Census regions, regardless of changes in incidence during this period, and was reflected in COVID-19–like illness-related ED visits, positive SARS-CoV-2 reverse transcription-polymerase chain reaction test results, and confirmed COVID-19 cases.<sup>12</sup>

Of the 599,636 (45%) cases with information on both race and ethnicity in US surveillance data collected between 22 January 2020 and 30 May 2020, 36% were non-Hispanic white, 33% were Hispanic, 22% were black, 4% were non-Hispanic Asian, 4% were non-Hispanic, other or multiple race, 1.3% were American Indian/Alaskan Native, and <1% were non-Hispanic Native Hawaiian or other Pacific Islander.<sup>11</sup> An increased rate ratio of COVID-19 cases and hospitalization compared to White, non-Hispanic has been reported for all other race and ethnicity groups, underlying factors including socioeconomic status, access to health care and occupations are likely to be the actual risk factors.<sup>13</sup>

**Table 1. Distribution and Estimated Cumulative Incidence of Reported Laboratory-Confirmed COVID-19 Cases, by Gender and Age Group — United States, 22 January – 30 May 2020<sup>a</sup>**

Age group (years)	Males		Females	
	Proportion (%)	Cumulative Incidence*	Proportion (%)	Cumulative Incidence*
0-9	1.7	52.5	1.4	49.7
10-19	3.8	113.4	3.7	121.4
20-29	13.3	370.0	14.3	434.6
30-39	16.8	492.8	15.8	490.5
40-49	17.0	547.0	16.2	536.2
50-59	18.4	568.8	17.3	533.0
60-69	14.5	526.9	12.7	434.6
70-79	8.2	513.7	7.7	422.7
$\geq 80$	6.4	842.0	10.8	940.0

a. Data from Stokes.<sup>11</sup>

\* Per 100,000 people

Among hospitalized cases with COVID-19 in the US, approximately 90% are over 40 years old, and between 58% to 66% are at least 60 years old.<sup>4,14</sup> The majority (approximately 60%) of COVID-19 patients admitted to hospitals in the US have been male.<sup>4,6,14,15,16,17,18</sup> African American COVID-19 patients have been reported to have an increased risk of hospitalization<sup>4,15</sup> and mortality,<sup>19</sup> compared to white patients in the US.

### **The main existing treatment options:**

At the time that this vaccine was in advanced development there were other vaccines in similar late-phase development including vaccines from Moderna (NCT04470427), Sinovac (NCT04456595), AstraZeneca (NCT04516746), Johnson & Johnson (NCT04505722), which may subsequently be approved, as may others currently in earlier development. The FDA on 18 December 2020 issued an emergency use authorization for the Moderna COVID-19 vaccine.

### **Natural history of the indicated condition in the untreated population, including mortality and morbidity:**

The natural history of COVID-19 is not yet fully understood. In the US, 14% of individuals testing positive for SARS-CoV-2 22 January – 30 May 2020 were reported to require hospitalization. The rate was lowest (<9%) among age groups <50 years, and highest among those older than 70 years (33%) and among patients with underlying health conditions (45.4%).<sup>11</sup>

Based on rates of severe disease reported in mainland China and assuming severe cases would be hospitalized, a demography-adjusted and under-ascertainment-adjusted model estimated the proportion of infected individuals requiring hospitalization. The proportions ranged from 8.2% in the age group 50-59 years to 18.4% in those older than 80 years. In the age groups below 50 years, less than 5% of infections were estimated to lead to hospitalization.<sup>20</sup>

Approximately 17% to 40% of those hospitalized with COVID-19 experience severe symptoms necessitating intensive care.<sup>5,7,15</sup> More than 75% of patients hospitalized with COVID-19 require supplemental oxygen.<sup>5,21</sup> The most common symptoms in hospitalized patients are fever (up to 90% of patients), dry cough (60%-86%), shortness of breath (53%-80%), fatigue (38%), nausea/vomiting or diarrhoea (15%-39%), and myalgia (15%-44%).<sup>7,14,17,21,22,23</sup> Complications of COVID-19 include impaired function of the heart, brain, lung, liver, kidney, and coagulation system.<sup>15,17,21</sup> Venous and arterial thromboembolic events occur in 10% to 25% in hospitalized patients with COVID-19 and in the ICU, venous and arterial thromboembolic events may occur in up to 31% to 59% of patients.<sup>21</sup>

As of 28 July 2020, the total number of COVID-19 related deaths in the EU and UK was over 100,000 and, in the US more than 150,000 people had died from COVID-19.<sup>3</sup> Overall reported mortality among hospitalized COVID-19 patients varies from 12.8% to 26% in Europe<sup>5,23,24</sup> and 20%-23% in the US.<sup>7,15,17</sup> In the US, studies have also reported up to 40% mortality in patients admitted to the ICU.<sup>14,15,17</sup> Age older than 60 years, male gender, hypertension, cardiovascular disease and chronic pulmonary disease, have been shown to be independently associated with in-hospital death of COVID-19 patients.<sup>7,14,24</sup>

### **Important co-morbidities:**

Important comorbidities in hospitalized COVID-19 patients include hypertension, diabetes, obesity, cardiovascular disease, chronic pulmonary disease or asthma, chronic kidney disease, cancer, and chronic liver disease.<sup>7,11,14,16,17,18,21</sup> Prevalence of these conditions have



been reported to be lower in mild cases and higher among fatal cases, as shown in Table 2 below.

**Table 2. Preconditions among COVID-19 Patients in EU/EEA and UK, by Severity of Disease. Case-based Data from TESSy Produced on 24 September 2020**

<b>Precondition</b>	<b>Mild % (N=66,257)</b>	<b>Hospitalized % (N=48,494)</b>	<b>Fatal % (N=12,796)</b>
Asplenia	0	0	0
Asthma	1.5	3.1	4.3
Cancer, malignancy	1.3	4.1	5.4
Cardiac disorder, excluding hypertension	3.9	12.1	16.1
Chronic lung disease, excluding asthma	3.0	6.3	9.2
Current smoking	2.4	0.3	0.3
Diabetes	2.8	11.6	14.2
Haematological disorders	0.1	0.7	0.6
HIV/other immune deficiency	0.5	1.6	1.8
Hypertension	2.2	9.0	18.4
Kidney-related condition, renal disease	0.6	4.1	8.1
Liver-related condition, liver disease	0.3	1.6	1.7
Neuromuscular disorder, chronic neurological	1.3	3.8	7.2
Obesity	0.6	0.3	0.1
Other endocrine disorder, excluding diabetes	0.2	0.3	0.2
Rheumatic diseases including arthritis	0	0.1	0
Tuberculosis	0	0	0
<b><i>None</i></b>	<b><i>79.3</i></b>	<b><i>41.2</i></b>	<b><i>12.4</i></b>

### **Module SII. Non-Clinical Part of the Safety Specification**

Nonclinical evaluation of BNT162b2 included pharmacology (mouse immunogenicity and NHP immunogenicity and challenge studies), pharmacokinetic (series of biodistribution, metabolism and pharmacokinetic studies), and toxicity (2 GLP rat repeat-dose toxicity) studies in vitro and in vivo. A DART study has been completed. No additional toxicity studies are planned for BNT162b2.

Nonclinical studies in mice and NHP for BNT162b2 (COVID-19 mRNA vaccine) demonstrated both a strong neutralizing antibody response and a Th1-type CD4<sup>+</sup> and an IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T-cell response. The Th1 profile is characterized by a strong IFN $\gamma$ , but not IL-4, response indicating the absence of a potentially deleterious Th2 immune response and is a pattern favored for vaccine safety and efficacy.<sup>25</sup> Rhesus macaques (Study VR-VRT-10671) that had received two IM immunizations with 100  $\mu$ g BNT162b2 or saline 21 days apart were challenged with  $1.05 \times 10^6$  plaque forming units of SARS-CoV-2 (strain USA-WA1/2020), split equally between the intranasal and intratracheal routes.<sup>26</sup> BNT162b2 provided complete protection from the presence of detectable viral RNA in the lungs compared to the saline control with no clinical, radiological or histopathological evidence of vaccine-elicited disease enhancement.

An intravenous rat PK study, using an LNP with the identical lipid composition as COVID-19 mRNA vaccine, demonstrated that the novel lipid excipients in the LNP formulation, ALC-0315 and ALC-0159, distribute from the plasma to the liver. While there was no detectable excretion of either lipid in the urine, the percent of dose excreted unchanged in feces was ~1% for ALC-0315 and ~50% for ALC-0159. Further studies indicated metabolism played a role in the elimination of ALC-0315. Biodistribution was assessed using luciferase expression as a surrogate reporter formulated like COVID-19 mRNA vaccine, with the identical lipid composition. After IM injection of the LNP-formulated RNA encoding luciferase in BALB/c mice, luciferase protein expression was demonstrated at the site of injection 6 hours post dose and expression decreased over time to almost reach background levels after 9 days. Luciferase was detected to a lesser extent in the liver; expression was present at 6 hours after injection and was not detected by 48 hours after injection. After IM administration of a radiolabeled LNP-mRNA formulation containing ALC-0315 and ALC-0159 to rats, the percent of administered dose was also greatest at the injection site. Outside of the injection site, total recovery of radioactivity was greatest in the liver and much lower in the spleen, with very little recovery in the adrenal glands and ovaries. The metabolism of ALC-0315 and ALC-0159 was evaluated in blood, liver microsomes, S9 fractions, and hepatocytes from mice, rats, monkeys, and humans. The in vivo metabolism was examined in rat plasma, urine, feces, and liver samples from the PK study. ALC-0315 and ALC-0159 are metabolized by hydrolytic metabolism of the ester and amide functionalities, respectively, and this hydrolytic metabolism is observed across the species evaluated.

In GLP toxicity studies, two variants of the COVID-19 mRNA vaccine candidate were tested, designated “variant 8” and “variant 9” (V8 and V9, respectively). The variants differ only in their codon optimization sequences which are designed to improve antigen expression, otherwise the amino acid sequences of the encoded antigens are identical.

COVID-19 mRNA vaccine (V9) was evaluated clinically and submitted for application. Two GLP-compliant repeat-dose toxicity studies were performed in Wistar Han rats; one with each variant. Both studies were 17 days in duration with a 3-week recovery period. A DART study in Wistar Han rats has been completed. Safety pharmacology, genotoxicity and carcinogenicity studies have not been conducted, in accordance with the 2005 WHO vaccine guideline.<sup>27</sup>

The IM route of exposure was selected for nonclinical investigation as it is the clinical route of administration. Rats were selected as the toxicology test species as they demonstrated an antigen-specific immune response to the vaccine and are routinely used for regulatory toxicity studies with an extensive historical safety database.

Administration of up to 100 µg COVID-19 mRNA vaccine by IM injection to male and female Wistar Han rats once every week, for a total of 3 doses, was tolerated without evidence of systemic toxicity. Expected inflammatory responses to the vaccine were evident such as oedema and erythema at the injection sites, transient elevation in body temperature, elevations in WBC and acute phase reactants, and lower A:G ratios. Injection site reactions were common in all vaccine-administered animals and were greater after boost immunizations. Changes secondary to inflammation included slight and transient reduction in body weights and transient reduction in reticulocytes, platelets and RBC mass parameters. Decreased reticulocytes were reported in rats treated with the licensed LNP-siRNA pharmaceutical Onpattro™ (NDA # 210922) but have not been observed in humans treated with this biotherapeutic<sup>28</sup> suggesting this is a species-specific effect. Decreased platelet counts were noted after repeat administration, but were small in magnitude of change, likely related to inflammation-related platelet activation and consumption, and unassociated with other alterations in haemostasis. Elevated levels of gamma-glutamyl transferase were observed in the first repeat-dose toxicity study with COVID-19 mRNA vaccine (V8) without evidence of cholestasis or hepatobiliary injury but was not recapitulated in the second repeat dose-toxicity study with COVID-19 mRNA vaccine (V9), the final clinical candidate. All changes in clinical pathology parameters and acute phase proteins were reversed at the end of the recovery phase for COVID-19 mRNA vaccine, with the exception of low magnitude higher red cell distribution width (consistent with a regenerative erythroid response) and lower A:G ratios (resulting from acute phase response) in animals administered COVID-19 mRNA vaccine. Macroscopic pathology and organ weight changes were also consistent with immune activation and inflammatory response and included increased size and/or weight of draining iliac lymph nodes and spleen. Vaccine-related microscopic findings at the end of the dosing phase consisted of oedema and inflammation in injection sites and surrounding tissues, increased cellularity in the draining iliac lymph nodes, bone marrow and spleen and hepatocyte vacuolation in the liver. Vacuolation of portal hepatocytes, the only test article-related liver microscopic finding, was not associated with any microscopic evidence of hepatic injury or hepatic functional effects (i.e., liver functional enzymes were not elevated) and may be associated with hepatocyte uptake of the LNP lipids.<sup>29</sup> Microscopic findings at the end of the dosing phase were partially or completely recovered in all animals at the end of the 3-week recovery period for COVID-19 mRNA vaccine. A robust immune response was elicited to the COVID-19 mRNA vaccine antigen.

In summary, the nonclinical safety findings related to COVID-19 mRNA vaccine administration primarily represent an expected immune reaction to vaccine administration and are clinically manageable or acceptable risks in the intended population. The key safety findings regarding COVID-19 mRNA vaccine from nonclinical studies and their relevance to human usage are presented in Table 3. There was no evidence of vaccine-elicited disease enhancement.

**Table 3. Key Safety Findings and Relevance to Human Usage**

Key Safety findings from Nonclinical Studies <sup>a,b</sup>	Relevance to Human Usage
<b>Pharmacology</b>	
<b>NHP Challenge Model</b> <ul style="list-style-type: none"> <li>No evidence of vaccine-elicited disease enhancement.</li> </ul>	<ul style="list-style-type: none"> <li>Suggests low risk of vaccine-enhanced disease in humans; being investigated in CTs.</li> </ul>
<b>Toxicity</b>	
<b>Injection site reactions:</b> <ul style="list-style-type: none"> <li>Injection site reactions were common and reversible or showed signs of reversibility at the end of the 3-week recovery period in nonclinical studies.</li> </ul> <b>Inflammation and immune activation:</b> <ul style="list-style-type: none"> <li>Evidence of inflammation or immune activation was common, reversible, and included transiently higher body temperature, higher circulating WBCs, and higher acute phase reactants. Secondly, transiently lower body weights, reticulocytes, platelets, and RBC mass parameters were observed.</li> </ul>	<ul style="list-style-type: none"> <li>In common with other vaccines, COVID-19 mRNA vaccine administration has the potential to generate injection site reactions such as oedema and erythema at the injection sites.</li> <li>In common with all vaccines, COVID-19 mRNA vaccine administration has the potential to generate inflammation which can lead to increased body temperature, higher circulating WBCs and higher acute phase proteins.</li> <li>Decreased reticulocytes have not been observed in humans treated with the LNP-siRNA pharmaceutical Onpatro<sup>28</sup>, suggesting this finding in rats is a species-specific effect.</li> <li>COVID-19 mRNA vaccine administration has the potential to transiently decrease platelets and RBC mass parameters. These slight decreases are not likely to be clinically meaningful due to their small magnitude.</li> </ul>
<b>Developmental and Reproductive Toxicity<sup>b</sup></b> <ul style="list-style-type: none"> <li>No vaccine-related effects on female fertility or the development of fetuses or offspring were observed in a DART study of BNT162b2 in rats.</li> </ul>	<ul style="list-style-type: none"> <li>No effects are anticipated in WOCBP, pregnant women or their offspring.</li> </ul>

a. Safety pharmacology, genotoxicity, and carcinogenicity studies were not conducted, in accordance with 2005 WHO vaccine guideline, as they are generally not considered necessary to support development and licensure of vaccines for infectious diseases.<sup>27</sup> In addition, the components of the vaccine construct are lipids and RNA and are not expected to have carcinogenic or genotoxic potential.

b. Based on audited study data. A DART study evaluating COVID-19 mRNA vaccine will be completed by 31-Mar-2021.

### Module SIII. Clinical Trial Exposure

BioNTech conducted a German first-in-human dose level–finding Phase 1/2 study (BNT162-01) to gather safety and immunogenicity data to enable evaluation of 4 vaccine candidates individually to inform the overall clinical development of a COVID-19 mRNA vaccine.

BNT162-01 is not conducted under the US IND application but is being conducted under a German Clinical Trial Application. The protocol for this study is provided in Module 5.3.5.1.

Four vaccine candidates were evaluated in Study BNT162-01. Based on safety and immunogenicity results from this study, 2 vaccine candidates, BNT162b1 and BNT162b2, were selected for evaluation in Study C4591001 (provided in Module 5.3.5.1), which is a Phase 1/2/3 randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy adults.

Phase 1 of Study C4591001 comprised dose-level–finding evaluations of the 2 selected vaccine candidates; multiple dose levels (some corresponding to those evaluated in Study BNT162-01) were evaluated. Study vaccine was administered using the same 2-dose schedule as in Study BNT162-01 (21 days apart). Dose levels were administered first to an 18- to 55-year age cohort, then to a 65- to 85-year age cohort.

Both vaccine candidate constructs were safe and well tolerated. BNT162b2 at the 30- $\mu$ g dose level was selected and advanced to the Phase 2/3 expanded cohort and efficacy evaluation primarily because:

- the reactogenicity profile for BNT162b2 was more favourable than BNT162b1 in both younger and older adults with similar immunogenicity results;
- in the NHP challenge study (VR-VTR-10671 – cross ref. with [Module SII](#)), a trend toward earlier clearance of BNT162b2 was observed in the nose.

Phase 2 of the study (for which enrolment has completed) comprised the evaluation of safety and immunogenicity data for the first 360 participants (180 from the active vaccine group and 180 from the placebo group, with each group divided between the younger and older age cohorts) entering the study after completion of Phase 1.

The Phase 3 part of the study (which is ongoing) evaluates the efficacy and safety in all participants (including the first 360 participants from Phase 2). Phase 3 introduced enrolment of adolescents 16 to 17 years of age to be evaluated with the 18- to 55-year-old cohort, as well as enrolment of a 12- to  $\leq$ 16-year-old cohort, and immunogenicity data from adolescents 12- to  $\leq$ 16 years of age are anticipated to bridge to the 16- to 25-year-old cohort.

The pivotal study was initially planned to enrol approximately 30,000 participants, which would have a probability of 78% of detecting an AE with a frequency of 0.01% (1/1000) and a probability of 95% of detecting an AE with a frequency of 0.02% (1/500). The protocol

was amended to enrol 44,000 participants, which slightly enhanced the ability to detect AEs. However, rarer events might not be detected.

Participants are planned to be followed for up to 24 months. This is particularly relevant for assessing the potential for late-occurring adverse reactions, such as the theoretical risk of VAED including VAERD.

The efficacy evaluation is event-driven, with prespecified interim analyses after accrual of at least 62, 92, and 120 cases and a final analysis at 164 cases.

Clinical study exposure data are being provided for ongoing studies as of 14 November 2020 for study C4591001 and as of 02 October 2020 for study BNT162-01.

At the DLP, a total of 43,734 participants were vaccinated in the COVID-19 mRNA vaccine clinical development program:

- 21,937 participants were exposed to BNT162b2 (COVID-19 mRNA vaccine), including 96 participants from study BNT162-01.
- 21,797 participants were exposed to PLACEBO (none from study BNT162-01).

Population for analysis of CTs data in this RMP includes the following 2 studies:

- C4591001: Phase 1/2/3, placebo-controlled, observer-blind, dose-finding, study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.
- BNT162-01: A multi-site, phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy adults.

Exposure to COVID-19 mRNA vaccine for participants in 2 ongoing studies by number of doses, and demographic characteristics is shown in [Table 4](#) through [Table 15](#).

In addition, exposure in clinical studies in special populations is provided in [Table 16](#).

**Table 4. Exposure to BNT162b2 by Age Group and Dose (C4591001)**

<b>Age Group Dose Exposure (Number of Doses Received)</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
<b>≥16 years to ≤17 years</b>		
Vaccine 30 µg		
1 Dose	61	61
2 Doses	77	154
Total	138	215
<b>≥18 years to ≤55 years</b>		
Vaccine 10 µg		
2 Doses	12	24
Total	12	24
Vaccine 20 µg		
2 Doses	12	24
Total	12	24
Vaccine 30 µg		
1 Dose	825	825
2 Doses	11830	23660
Total	12655	24485
<b>&gt;55 years</b>		
Vaccine 10 µg		
2 Doses	12	24
Total	12	24

**Table 4. Exposure to BNT162b2 by Age Group and Dose (C4591001)**

<b>Age Group Dose Exposure (Number of Doses Received)</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Vaccine 20 µg		
2 Doses	12	24
Total	12	24
Vaccine 30 µg		
1 Dose	323	323
2 Doses	8629	17258
Total	8952	17581

Note: 30 µg includes data from phase 1 and phase 2/3.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 19NOV2020 (00:22) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/adsl\_s912



**Table 5. Exposure to BNT162b2 by Age Group and Dose (BNT162-01)**

<b>Age Group Dose Exposure (Number of Doses Received)</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>≥18 years to ≤55 years</b>		
Vaccine 1 µg		
1 Dose	1	1
2 Doses	11	22
Total	12	23
Vaccine 3 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24
Vaccine 10 µg		
1 Dose	1	1
2 Doses	11	22
Total	12	23
Vaccine 20 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24

**Table 5. Exposure to BNT162b2 by Age Group and Dose (BNT162-01)**

<b>Age Group Dose Exposure (Number of Doses Received)</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 30 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24
<b>&gt;55 years</b>		
Vaccine 1 µg		
1 Dose	0	0
2 Doses	0	0
Total	0	0
Vaccine 3 µg		
1 Dose	0	0
2 Doses	0	0
Total	0	0
Vaccine 10 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24

**Table 5. Exposure to BNT162b2 by Age Group and Dose (BNT162-01)**

<b>Age Group Dose Exposure (Number of Doses Received)</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 20 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24
Vaccine 30 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2020 (21:23) Source Data: adsl Table Generation: 18NOV2020 (14:42) (Cutoff date:02OCT2020, Snapshot Date: 02OCT2020)  
Output File: ex\_b2\_age\_dose2.rtf

**Table 6. Exposure to BNT162b2 by Age Group and Dose – Children and Elderly Subjects (C4591001)**

<b>Age Group Dose Exposure (Number of Doses Received)</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
<b>≥12 years to ≤15 years</b>		
Vaccine 30 µg		
1 Dose	1	1
2 Doses	48	96
Total	49	97
<b>≥65 years</b>		
Vaccine 10 µg		
2 Doses	12	24
Total	12	24
Vaccine 20 µg		
2 Doses	12	24
Total	12	24
Vaccine 30 µg		
1 Dose	121	121
2 Doses	4435	8870
Total	4556	8991

Note: 30 µg includes data from phase 1 and phase 2/3.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 19NOV2020 (00:22) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/adsl\_s913

**Table 7. Exposure to BNT162b2 by Dose (Totals) (C4591001)**

<b>Dose Exposure (Number of Doses Received)</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Vaccine 10 µg		
2 Doses	24	48
Total	24	48
Vaccine 20 µg		
2 Doses	24	48
Total	24	48
Vaccine 30 µg		
1 Dose	1209	1209
2 Doses	20536	41072
Total	21745	42281

Note: 30 µg includes data from phase 1 and phase 2/3.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 19NOV2020 (00:22) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/adsl\_s922

**Table 8. Exposure to BNT162b2 by Dose (Totals) (BNT162-01)**

<b>Dose Exposure (Number of Doses Received)</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 1 µg		
1 Dose	1	1
2 Doses	11	22
Total	12	23
Vaccine 3 µg		
1 Dose	0	0
2 Doses	12	24
Total	12	24
Vaccine 10 µg		
1 Dose	1	1
2 Doses	23	46
Total	24	47
Vaccine 20 µg		
1 Dose	0	0
2 Doses	24	48
Total	24	48

**Table 8. Exposure to BNT162b2 by Dose (Totals) (BNT162-01)**

<b>Dose Exposure (Number of Doses Received)</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 30 µg		
1 Dose	0	0
2 Doses	24	48
Total	24	48

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2020 (21:23) Source Data: adsl Table Generation: 17NOV2020 (13:08) (Cutoff date:02OCT2020, Snapshot Date: 02OCT2020)  
Output File: ex\_b2\_dose.rtf

**Table 9. Exposure to BNT162b2 by Dose, Age Group, and Gender (C4591001)**

Dose Age Group	Number of Subjects Exposed to BNT162b2		Total Number of Vaccine Doses	
	Male	Female	Male	Female
Vaccine 10 µg				
≥18 years to ≤55 years	5	7	10	14
>55 years	2	10	4	20
Total	7	17	14	34
Vaccine 20 µg				
≥18 years to ≤55 years	6	6	12	12
>55 years	5	7	10	14
Total	11	13	22	26
Vaccine 30 µg				
≥16 years to ≤17 years	75	63	117	98
≥18 years to ≤55 years	6437	6218	12397	12088
>55 years	4680	4272	9177	8404
Total	11192	10553	21691	20590

Note: 30 µg includes data from phase 1 and phase 2/3.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 19NOV2020 (00:22) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/adsl\_s932



**Table 10. Exposure to BNT162b2 by Dose, Age Group, and Gender (BNT162-01)**

<b>Dose Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>		<b>Total No. of Vaccine Doses</b>	
	<b>Male</b>	<b>Female</b>	<b>Male</b>	<b>Female</b>
Vaccine 1 µg				
≥18 years to ≤55 years	7	5	14	9
>55 years	0	0	0	0
Total	7	5	14	9
Vaccine 3 µg				
≥18 years to ≤55 years	5	7	10	14
>55 years	0	0	0	0
Total	5	7	10	14
Vaccine 10 µg				
≥18 years to ≤55 years	4	8	8	15
>55 years	8	4	16	8
Total	12	12	24	23
Vaccine 20 µg				
≥18 years to ≤55 years	2	10	4	20
>55 years	6	6	12	12
Total	8	16	16	32

**Table 10. Exposure to BNT162b2 by Dose, Age Group, and Gender (BNT162-01)**

<b>Dose Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>		<b>Total No. of Vaccine Doses</b>	
	<b>Male</b>	<b>Female</b>	<b>Male</b>	<b>Female</b>
Vaccine 30 µg				
≥18 years to ≤55 years	8	4	16	8
>55 years	4	8	8	16
Total	12	12	24	24

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2020 (21:23) Source Data: adsl Table Generation: 18NOV2020 (15:12) (Cutoff date:02OCT2020, Snapshot Date: 02OCT2020)

Output File: ex\_b2\_age\_dose\_sex2.rtf

**Table 11. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (C4591001)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Subjects $\geq 16$ years to $\leq 17$ years		
Vaccine 30 $\mu\text{g}$		
Racial Origin		
White	102	158
Black or African American	21	35
Asian	7	8
Native Hawaiian or other Pacific Islander	2	4
Multiracial	6	10
Total	138	215
Ethnic Origin		
Hispanic/Latino	17	24
Non-Hispanic/non-Latino	121	191
Total	138	215
Subjects $\geq 18$ years to $\leq 55$ years		
Vaccine 10 $\mu\text{g}$		
Racial Origin		
White	11	22
Asian	1	2
Total	12	24
Ethnic Origin		
Hispanic/Latino	1	2
Non-Hispanic/non-Latino	11	22
Total	12	24

**Table 11. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (C4591001)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Vaccine 20 µg		
Racial Origin		
White	10	20
Black or African American	2	4
Total	12	24
Ethnic Origin		
Hispanic/Latino	1	2
Non-Hispanic/non-Latino	11	22
Total	12	24
Vaccine 30 µg		
Racial Origin		
White	9917	19153
Black or African American	1400	2725
Asian	681	1332
American Indian or Alaska Native	118	211
Native Hawaiian or other Pacific Islander	40	79
Multiracial	418	825
Not reported	81	160
Total	12655	24485
Ethnic Origin		
Hispanic/Latino	4001	7807
Non-Hispanic/non-Latino	8590	16557

**Table 11. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (C4591001)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Not reported	64	121
Total	12655	24485
Subjects >55 years		
Vaccine 10 µg		
Racial Origin		
White	12	24
Total	12	24
Ethnic Origin		
Non-Hispanic/non-Latino	12	24
Total	12	24
Vaccine 20 µg		
Racial Origin		
White	12	24
Total	12	24
Ethnic Origin		
Non-Hispanic/non-Latino	12	24
Total	12	24
Vaccine 30 µg		
Racial Origin		
White	7842	15403
Black or African American	671	1312

**Table 11. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (C4591001)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Asian	248	490
American Indian or Alaska Native	42	80
Native Hawaiian or other Pacific Islander	15	29
Multiracial	112	223
Not reported	22	44
Total	8952	17581
<b>Ethnic Origin</b>		
Hispanic/Latino	1655	3254
Non-Hispanic/non-Latino	7241	14215
Not reported	56	112
Total	8952	17581

Note: 30 µg includes data from phase 1 and phase 2/3.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 19NOV2020 (00:22) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/adsl\_s942

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Dose</b>		
<b>Race/Ethnic Origin</b>		
<b>Subjects ≥18 to ≤55 years</b>		
Vaccine 1 µg		
Racial Origin		
White	12	23
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	23
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	23
Not reported	0	0
Unknown	0	0
Total	12	23

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Dose</b>		
<b>Race/Ethnic Origin</b>		
<b>Subjects ≥18 to ≤55 years</b>		
Vaccine 3 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24



**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Subjects ≥18 to ≤55 years</b>		
Vaccine 10 µg		
Racial Origin		
White	12	23
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	23
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	23
Not reported	0	0
Unknown	0	0
Total	12	23

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Subjects ≥18 to ≤55 years</b>		
Vaccine 20 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Subjects ≥18 to ≤55 years</b>		
Vaccine 30 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Dose</b>		
<b>Race/Ethnic Origin</b>		
<b>Subjects &gt;55 to ≤85 years</b>		
Vaccine 1 µg		
Racial Origin		
White	0	0
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	0	0
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	0	0
Not reported	0	0
Unknown	0	0
Total	0	0

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group Dose Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Subjects &gt;55 to ≤85 years</b>		
Vaccine 3 µg		
Racial Origin		
White	0	0
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	0	0
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	0	0
Not reported	0	0
Unknown	0	0
Total	0	0

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Dose</b>		
<b>Race/Ethnic Origin</b>		
<b>Subjects &gt;55 to ≤85 years</b>		
Vaccine 10 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Dose</b>		
<b>Race/Ethnic Origin</b>		
<b>Subjects &gt;55 to ≤85 years</b>		
Vaccine 20 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24

**Table 12. Exposure to BNT162b2 by Age Group, Dose, and Race/Ethnic Origin (BNT162-01)**

<b>Age Group</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Dose</b>		
<b>Race/Ethnic Origin</b>		
Subjects >55 to ≤85 years		
Vaccine 30 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2020 (21:23) Source Data: adsl Table Generation: 17NOV2020 (12:53) (Cutoff date:02OCT2020, Snapshot Date: 02OCT2020)

Output File: ex\_b2\_age\_dose\_race.rtf



<b>Table 13. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (C4591001)</b>		
<b>Dose Race/Ethnic Origin</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Vaccine 10 µg		
Racial Origin		
White	23	46
Asian	1	2
Total	24	48
Ethnic Origin		
Hispanic/Latino	1	2
Non-Hispanic/non-Latino	23	46
Total	24	48
Vaccine 20 µg		
Racial Origin		
White	22	44
Black or African American	2	4
Total	24	48
Ethnic Origin		
Hispanic/Latino	1	2
Non-Hispanic/non-Latino	23	46
Total	24	48
Vaccine 30 µg		
Racial Origin		
White	17861	34714
Black or African American	2092	4072
Asian	936	1830
American Indian or Alaska Native	160	291

**Table 13. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (C4591001)**

<b>Dose Race/Ethnic Origin</b>	<b>Number of Subjects Exposed to BNT162b2</b>	<b>Total Number of Vaccine Doses</b>
Native Hawaiian or other Pacific Islander	57	112
Multiracial	536	1058
Not reported	103	204
Total	21745	42281
Ethnic Origin		
Hispanic/Latino	5673	11085
Non-Hispanic/non-Latino	15952	30963
Not reported	120	233
Total	21745	42281

Note: 30 µg includes data from phase 1 and phase 2/3.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adsl Table Generation: 19NOV2020 (00:23) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/adsl\_s952

**Table 14. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (BNT162-01)**

<b>Dose</b> <b>Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 1 µg		
Racial Origin		
White	12	23
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	23
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	23
Not reported	0	0
Unknown	0	0
Total	12	23

**Table 14. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (BNT162-01)**

<b>Dose</b> <b>Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 3 µg		
Racial Origin		
White	12	24
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	12	24
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	12	24
Not reported	0	0
Unknown	0	0
Total	12	24

**Table 14. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (BNT162-01)**

<b>Dose</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Race/Ethnic Origin</b>		
Vaccine 10 µg		
Racial Origin		
White	24	47
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	24	47
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	24	47
Not reported	0	0
Unknown	0	0
Total	24	47

**Table 14. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (BNT162-01)**

<b>Dose</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
<b>Race/Ethnic Origin</b>		
Vaccine 20 µg		
Racial Origin		
White	24	48
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	24	48
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	24	48
Not reported	0	0
Unknown	0	0
Total	24	48

**Table 14. Exposure to BNT162b2 by Dose and Race/Ethnic Origin (BNT162-01)**

<b>Dose Race/Ethnic Origin</b>	<b>No. of Subjects Exposed to BNT162b2</b>	<b>Total No. of Vaccine Doses</b>
Vaccine 30 µg		
Racial Origin		
White	24	48
Black or African American	0	0
Asian	0	0
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Not Reported	0	0
Unknown	0	0
Total	24	48
Ethnic Origin		
Hispanic/Latino	0	0
Non-Hispanic/non-Latino	24	48
Not reported	0	0
Unknown	0	0
Total	24	48

PFIZER CONFIDENTIAL SDTM Creation: 03NOV2020 (21:23) Source Data: adsl Table Generation: 17NOV2020 (13:09) (Cutoff date:02OCT2020, Snapshot Date: 02OCT2020)  
Output File: ex\_b2\_dose\_race.rtf

**Table 15. Exposure to BNT162b2 (30 µg) by Special Population (C4591001)**

Population	Number of Subjects Exposed to BNT162b2 (30 µg) (N <sup>a</sup> = 21720) n <sup>b</sup>	Total Number of Vaccine Doses
Subjects with any baseline comorbidity	10017	25215
AIDS/HIV	99	177
Any Malignancy + Metastatic Solid Tumor + Leukemia + Lymphoma	845	1660
Chronic Pulmonary Disease	1730	3379
Renal Disease	139	274
Rheumatic Disease	75	142
Mild Liver Disease + Moderate or Severe Liver Disease	145	282
Cerebrovascular Disease + Peripheral Vascular Disease + Myocardial Infarction + Congestive Heart Failure	645	1265
Dementia	7	14
Diabetes With/Without Chronic Complication	1693	3301
Hemiplegia or Paraplegia	4	8



**Table 15. Exposure to BNT162b2 (30 µg) by Special Population (C4591001)**

Population	Number of Subjects Exposed to BNT162b2 (30 µg) (N <sup>a</sup> = 21720) n <sup>b</sup>	Total Number of Vaccine Doses
Peptic Ulcer Disease	62	120
Obese (≥30.0 kg/m <sup>2</sup> )	7488	14593

Note: Comorbidity is based Charlson Comorbidity Index categories. Participants identified as belonging to these categories were identified by medical history data collected during the study.

Note: 30 µg includes data from phase 1 and phase 2/3.

Note: Hemiplegia or Paraplegia only includes preferred terms Hemiplegia and Paraplegia.

a. n = Number of subjects reporting at least 1 occurrence of any comorbidity or BMI (≥30.0 kg/m<sup>2</sup>).

b. N = number of subjects in the specified group.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:04) Source Data: admh Table Generation: 18NOV2020 (23:16) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001\_RMP\_Phase1\_2\_3/admh\_s953

## **Module SIV. Populations Not Studied in Clinical Trials**

### **SIV.1. Exclusion Criteria in Pivotal Clinical Studies Within the Development Programme**

Detailed descriptions of all inclusion and exclusion criteria for clinical studies are provided in the individual CSRs which were filed in Module 5.3.5.1.

#### **Inclusion criteria**

- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Healthy participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrolment, can be included. In order for the overall Phase 3 study population to be as representative and diverse as possible, the inclusion of participants with known chronic stable infection with HIV, HCV, or HBV was permitted as the study progressed. Specific criteria for these Phase 3 participants can be found in the C4591001 protocol, Section 10.8 (please refer to Module 5.3.5.1).
- Phase 2/3 only: Participants who, in the judgment of the investigator, are at higher risk for acquiring COVID-19 (including, but not limited to, use of mass transportation, relevant demographics, front-line essential workers and others).

#### **Exclusion criteria**

The participants enrolled were 12 years of age and older; with the 12- to ≤16-year-old cohort most recently being included in the protocol. Phase 1 exclusion criteria were stricter than criteria in Phases 2 and 3 of the study. Participants were excluded from the studies according to the general criteria listed below:

- **Previous vaccination with any coronavirus vaccine**

Reason for exclusion: To avoid confounding the assessment of serological or clinical immune response in the study population.

Is it considered to be included as missing information? No.

Rationale: Minimal potential clinical impact on the target population.

- **Previous clinical or microbiological diagnosis of COVID-19**

Reason for exclusion: Phase 1 excluded participants with a previous clinical or microbiological diagnosis of COVID-19 because these participants may have some degree of protection from subsequent infection by SARS-CoV-2 and therefore would confound the pivotal efficacy endpoint. During Phase 2/3, participants with prior undiagnosed infection were allowed to be enrolled. Screening for SAR-CoV-2 with

nucleic acid amplification test by nasal swab or antibodies to non-vaccine SARS-CoV-2 antigen by serology was not conducted before vaccine administration in Phase 2/3, but samples were taken to run these assays after vaccination, thus identifying participants with unidentified prior infection. This group will be assessed to identify whether prior infection affects safety.

Is it considered to be included as missing information? No.

Rationale: Safety in study participants with prior infection will be assessed in the pivotal study.

- **Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination**

Reason for exclusion: Immunocompromised participants may have impaired immune responses to vaccines and would therefore limit the ability to demonstrate efficacy, which is the primary pivotal endpoint.

Is it considered to be included as missing information? Yes.

Rationale: Participants with potential immunodeficient status were not specifically included in the study population. However, since the study population is intended to be as representative as possible of the vulnerable population to COVID-19 illness, sub-analyses of immunogenicity data in future studies may provide further understanding of immune responses in this population.

- **Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study**

Reason for exclusion: To avoid confounding the assessment of serological or clinical immune response in the study population.

Is it considered to be included as missing information? No.

Rationale: No impact on the safety of the target population.

- **Women who are pregnant or breastfeeding**

Reason for exclusion: To avoid use in a vulnerable population.

Is it considered to be included as missing information? Yes.

Rationale: It is not known if maternal vaccination with COVID-19 mRNA vaccine would have unexpected negative consequences to the embryo or foetus.

- **Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study**

Reason for exclusion: To avoid misleading results deriving from non-compliance to study procedures.

Is it considered to be included as missing information? No.

Rationale: Safety profile of COVID-19 mRNA vaccine is not expected to differ in these subjects when properly administered.

#### **SIV.2. Limitations to Detect Adverse Reactions in Clinical Trial Development Programmes**

The clinical studies are limited in size and, therefore, unlikely to detect very rare adverse reactions, or adverse reactions with a long latency.

#### **SIV.3. Limitations in Respect to Populations Typically Under-Represented in Clinical Trial Development Programmes**

There has been limited exposure to COVID-19 mRNA vaccine in some special populations and no epidemiologic studies have been conducted in pregnant/breastfeeding women, paediatric participants (<16 years of age), and specific subpopulations that were excluded from the data.

**Table 16. Exposure of Special Populations included or not in Clinical Trial Development Programmes**

Type of special population	Exposure
Pregnant women	<p>Available data on COVID-19 mRNA vaccine administered to pregnant women are insufficient to inform on vaccine-associated risks in pregnancy. Therefore, administration of Comirnaty in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.</p> <p>Through the DLP, there were 11 cases (11 events) originating from Study C4591001, and all were unique pregnancies.</p>
Breastfeeding women	<p>Breastfeeding women were not included in the COVID-19 mRNA vaccine clinical development program.</p> <p>Data are not available to assess the effects of COVID-19 mRNA vaccine on the breastfed infant or on milk production/excretion.</p> <p>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for COVID-19 mRNA vaccine and any potential adverse effects on the breastfed newborn/infant/toddler from COVID-19 mRNA vaccine or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptible to disease prevented by the vaccine.</p> <p>There were no CT cases indicative of exposure during breastfeeding.</p>

**Table 16. Exposure of Special Populations included or not in Clinical Trial Development Programmes**

Type of special population	Exposure
	Women who were breastfeeding were excluded from study participation.
Participants with relevant comorbidities: <ul style="list-style-type: none"> <li>• Participants with hepatic impairment</li> <li>• Participants with renal impairment</li> <li>• Participants with cardiovascular disease</li> <li>• Immunocompromised participants</li> <li>• Participants with a disease severity different from inclusion criteria in CTs</li> </ul>	Healthy participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrolment, were included. This allowed enrolment of a proportion of participants with common comorbidities such as cardiovascular diseases including hypertension, chronic pulmonary diseases, asthma, chronic liver disease, BMI >30 kg/m <sup>2</sup> , participants with stage 3 or worse chronic kidney disease, and participants with varying disease severity.  Please refer to <a href="#">Table 15</a> for the exposure of special populations.  Participants with potential immunodeficient status were not specifically included in the study population.
Population with relevant different ethnic origin	Please refer to <a href="#">Table 11</a> to <a href="#">Table 14</a> for exposure information by ethnic origin from the studies.
Subpopulations carrying relevant genetic polymorphisms	No data available.
Paediatric participants	The safety and effectiveness in individuals younger than 16 years of age have not yet been established. The use in adolescents aged between 12 and 15 years is not in scope for the proposed indication. Forty-nine (49) children 12 to 15 years of age received COVID-19 mRNA vaccine ( <a href="#">Table 6</a> ).
Elderly (≥65 years old)	Clinical studies of COVID-19 mRNA vaccine included 4580 participants 65 years of age and over ( <a href="#">Table 6</a> ).

Abbreviations: BMI = body mass index; CT = clinical trial; DLP = data lock point.

## Module SV. Post-Authorisation Experience

### SV.1. Post-Authorisation Exposure

As of 17 December 2020, COVID-19 mRNA vaccine (BNT162b2) has not been marketed in any country/region. The number of individuals who have been vaccinated under temporary authorization or emergency use authorisation is not available.

The available information related to COVID-19 mRNA vaccine shipment through 17 December 2020, is provided below.

<b>Countries</b>	<b>Total Number of Doses</b>
United States	2,823,600
United Kingdom	2,464,800
Israel	340,275
Puerto Rico	33,150
N Mariana Islands	5850
American Samoa	5850
Saudi Arabia	4875
Guam	3900
US Virgin Islands	975
<b>Total</b>	<b>5,683,275</b>

**SV.1.1. Method Used to Calculate Exposure**

Not applicable.

**SV.1.2. Exposure**

Not applicable.

## Module SVI. Additional EU Requirements for the Safety Specification

### Potential for misuse for illegal purposes

COVID-19 mRNA vaccine does not have characteristics that would make it attractive for use for illegal purposes; therefore, there is only a low potential for COVID-19 mRNA vaccine misuse for illegal purposes.

### Module SVII. Identified and Potential Risks

In accordance with EMA RMP guidance for COVID-19 vaccines, the below factors were taken into consideration for the generation of the safety specification and are not determined to be identified or potential risks.

- **The vaccine construct and the formulation.** The COVID-19 mRNA vaccine consists of non-infectious, non-replicating RNA in a lipid-based formulation, which delivers the RNA to cells in the immunized person. Protein expression from the RNA is transient, and as is RNA itself. There is no toxicity associated with the LNP or its metabolism (Study reports 38166 and 20GR142). Vacuolation of hepatocytes was observed in rat toxicity studies and believed to be associated with the uptake of the LNP and was without evidence of any effect on liver function. The liver vacuolation was reversed approximately 3-weeks after the last administration.
- **The degradation of the active substance / antigen and potential impact on safety related to this; (e.g. for mRNA-based vaccines).** Like endogenous mRNA in the cytosol, vaccine RNA in cytosol is degraded. The COVID-19 mRNA contains no known toxic products of the degradation of the RNA or the lipids in the formulation.
- The vaccine does not contain an adjuvant.

#### SVII.1. Identification of Safety Concerns in the Initial RMP Submission

The safety concerns of COVID-19 mRNA vaccine in the initial RMP are listed in Table 17.

**Table 17. Summary of Safety Concerns**

Important Identified Risks	Anaphylaxis
Important Potential Risks	Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)
Missing Information	Use in pregnancy and while breast feeding
	Use in immunocompromised patients
	Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)
	Use in patients with autoimmune or inflammatory disorders
	Interaction with other vaccines
	Long term safety data

### **SVII.1.1. Risks not Considered Important for Inclusion in the List of Safety Concerns in the RMP**

Not all potential or identified risks for the vaccine are considered to meet the level of importance necessitating inclusion in the list of safety concerns in the RMP.

#### **Reasons for not including an identified or potential risk in the list of safety concerns in this RMP include:**

Risks with minimal and temporary clinical impact on patients (in relation to the severity of the disease prevented).

*The following reactogenicity events are identified risks not considered as Important: Injection site pain, Injection site swelling and Injection site redness, Fever, Chills, Fatigue, Headache, Muscle pain, and Joint pain.*

Very rare potential risks for any medicinal treatment, including vaccines, which are well known to healthcare professionals are not included in the list of safety concerns.

In acknowledgment of the EMA core RMP19 guidance, the reactogenicity profile of COVID-19 mRNA vaccine is discussed below with respect to observed differences in solicited reactogenicity systemic events between Dose 1 and Dose 2. The observed differences do not impact the safety profile of the vaccine and are not proposed to be included in the list of safety concerns, rather they are discussed for completeness in the presentation of the safety profile.

#### **Reactogenicity**

At the time of the safety cut-off date (14 November 2020), the Phase 2/3 reactogenicity subset was comprised of 8183 participants ( $\geq 12$  years of age), which included the 360 participants in Phase 2. The reactogenicity data were collected by participants' e-diary for reporting prompted local reactions and systemic events for 7 days after each dose. Adolescents 12 to 15 years of age were analysed in a separate group; these are preliminary data provided in support of the EUA indication which is for  $\geq 16$  years of age.

- ***Local Reactions***

In the BNT162b2 group, pain at the injection site was reported more frequently in the younger group (16-55 years) than in the older group ( $> 55$  years), and frequency was similar after Dose 1 compared with Dose 2 of BNT162b2 in the younger group (83.1% vs 77.8%) and in the older group (71.1% vs 66.1%).

In the BNT162b2 group, frequencies of redness and swelling were similar in the younger and older age group after Doses 1 and 2. Frequencies of redness were similar after Dose 1 compared with Dose 2 of BNT162b2 in the younger age group (4.5% vs 5.9%) and in the older age group (4.7% vs 7.2%). Frequencies of swelling were similar after Dose 1 compared with Dose 2 of BNT162b2 in the younger age group (5.8% vs 6.3%, respectively) and in the older age group (6.5% vs 7.5%). In the placebo group, redness and swelling were reported infrequently in the younger ( $\leq 1.1\%$ ) and older ( $\leq 1.1\%$ ) groups after Doses 1 and 2.



Overall, across age groups, pain at the injection site did not increase after Dose 2, and redness and swelling were generally similar in frequency after Dose 1 and Dose 2. Most local reactions were mild or moderate in severity. Few severe local reactions were reported after either dose. The frequency of any severe local reactions after Dose 1 and after Dose 2 was  $\leq 0.6\%$ . No grade 4 (potentially life-threatening) reactions were reported.

Across age groups, local reactions for the BNT162b2 group after either dose had a median onset day between Day 1 and Day 3 (Day 1 was the day of vaccination) and ranges were similar in the younger and older age groups. Across age groups, local reactions for this group after either dose resolved with median durations between 1 to 2 days, which were similar in the younger and older age groups.

No clinically meaningful differences in local reactions were observed by age and/or or baseline SARS-CoV-2 status subgroups.

- **Systemic Events**

Systemic events were generally increased in frequency and severity in the younger age group (16-55 years) compared with the older age group (> 55 years), with frequencies and severity increasing with number of doses (Dose 1 vs Dose 2). Vomiting and diarrhoea were exceptions, with vomiting reported similarly infrequently in both age groups and diarrhoea reported at similar incidences after each dose.

Systemic events in the younger group compared with the older group, with frequencies increasing with number of doses (Dose 1 vs Dose 2), were:

fatigue: younger group (47.4% vs 59.4%) compared to older group (34.1% vs 50.5%)

- headache: younger group (41.9% vs 51.7%) compared to older group (25.2% vs 39.0%)
- muscle pain: younger group (21.3% vs 37.3%) compared to older group (13.9% vs 28.7%)
- chills: younger group (14.0% vs 35.1%) compared to older group (6.3% vs 22.7%)
- joint pain: younger group (11.0% vs 21.9%) compared to older group (8.6% vs 18.9%)
- fever: younger group (3.7% vs 15.8%) compared to older group (1.4% vs 10.9%)
- vomiting: reported less frequently in the older group and was similar after either dose
- diarrhoea: reported less frequently in the older group and was similar after each dose.
- Systemic events were generally reported less frequently in the placebo group than in the BNT162b2 group, for both age groups and doses, with some exceptions. In the younger age group, vomiting and diarrhoea (after Dose 1 and Dose 2) were reported at similar frequencies in the placebo group and the BNT162b2 group. In the older age group, fever and joint pain (after Dose 1) and vomiting and diarrhoea (after Dose 1 and Dose 2) were reported at similar frequencies in the placebo group and the BNT162b2 group.

Following both Dose 1 and Dose 2, use of antipyretic/pain medication was slightly less frequent in the older age group (19.9% vs 37.7%) than in the younger age group (27.8% vs 45.0%) after both doses, and medication use increased in both age groups after Dose 2 as compared with after Dose 1. Use of antipyretic/pain medication was less frequent in the

placebo group than in the BNT162b2 group and was similar after Dose 1 and Dose 2 in the younger and older placebo groups (9.8% to 22.0%).

After the first and second dose and in both age groups, the majority of systemic events were mild or moderate in severity. Systemic events across age groups after Dose 1 of BNT162b2 were generally lower in frequency than after Dose 2: fever (2.7% vs 13.6%), fatigue (41.5% vs 55.5%), headache (34.5% vs 46.1%), chills (10.6% vs 29.6%), muscle pain (18.0% vs 33.5%), and joint pain (9.9% vs 20.5). Diarrhoea and vomiting frequencies were generally similar. The frequency of any severe systemic event after Dose 1 was  $\leq 0.9\%$ . After Dose 2, systemic events had frequencies of  $< 2\%$  with the exception of fatigue (3.8%) and headache (2.0%).

In the placebo group, severe fever was reported at a similar frequency ( $\leq 0.4\%$ ) after Dose 1 and Dose 2. One participant in the younger BNT162b2 group reported fever of 41.2°C only on Day 2 after Dose 2 and was nonfebrile for all other days of the reporting period. One other participant in the younger group reported fever that reached a high temperature of 42.3°C on Day 4 after Dose 1 that lasted in total for 3 days; the participant was nonfebrile at the end of the reporting period.

Across age groups, median onset day for most systemic events after either dose of BNT162b2 was Day 2 to Day 3 (Day 1 was the day of vaccination), and ranges were similar in the younger and older age groups. Across age groups, all systemic events resolved with median duration of 1 day, which was similar in the younger and older age groups.

Other than fatigue and headache, most systemic events were infrequent in placebo recipients.

Antipyretic/pain medication use in the younger adolescent group was modestly increased after Dose 2 compared to Dose 1 (30.6% vs 41.3%) and was greater than use in the placebo group (9.8% vs 13%).

No clinically meaningful differences in systemic events were observed by age and/or baseline SARS-CoV-2 status subgroups. In summary, increases in some systemic reactogenicity events (fever, chills, headache, fatigue, muscle pain and joint pain) were observed in the week following Dose 2 when compared with the week following Dose 1. The differences are small enough that they are unlikely to discourage vaccinees from completing the full 2-dose regimen for vaccination neither do they impact the benefit risk profile of the vaccine overall. Overall, the reactogenicity events have only temporary clinical impact on patients in relation to the potential severity of the disease prevented.

### **Adverse Events of Special Interest (AESI)**

COVID-19 mRNA vaccine study C4591001 did not pre-specify AESI however, Pfizer utilizes a dynamic list of TME terms to be highlighted in clinical study safety data review. TMEs include events of interest due to their association with COVID-19 and terms of interest for vaccines in general and may include Preferred Terms, High Level Terms, High Level Group Terms or Standardised MedDRA Queries.

For the purpose of the RMP and summary safety reports, an AESI list was composed taking into consideration the available lists of AESIs from the following expert groups and regulatory authorities:

Brighton Collaboration (SPEAC)<sup>30</sup>

- ACCESS protocol<sup>31</sup>
- US CDC (preliminary list of AESI for VAERS surveillance)<sup>32</sup>
- MHRA (unpublished guideline).

The AESI list is comprised of medical conditions to allow for changes and customization of MedDRA terms as directed by AE reports and the evolving safety profile of the vaccine:

- Immune/Autoimmune-mediated neurological, haematological and vasculitis events;
- Events associated with severe COVID-19;
- Serious thrombotic and embolic events.

The AESIs are taken in consideration for all routine and additional pharmacovigilance activities.

### **SVII.1.2. Risks Considered Important for Inclusion in the List of Safety Concerns in the RMP**

#### **Important Identified Risk: Anaphylaxis**

##### Risk-benefit impact

Anaphylaxis is a serious adverse reaction that, although very rare, can be life-threatening.

#### **Important Potential Risk: Vaccine-Associated Enhanced Disease (VAED), including Vaccine-Associated Enhanced Respiratory Disease (VAERD)**

##### Risk-benefit impact

Although not observed or identified in clinical studies with COVID-19 vaccines, there is a theoretical risk, mostly based on non-clinical betacoronavirus data, of VAED occurring either before the full vaccine regimen is administered or in vaccinees who have waning immunity over time. If VAED were to be identified as a true risk, depending on its incidence and severity, it may negatively impact the overall vaccine benefit risk assessment for certain individuals.

#### **Missing Information: Use in Pregnancy and while breast feeding**

##### Risk-benefit impact

The safety profile of the vaccine is not known in pregnant or breastfeeding women due to their exclusion from the pivotal clinical study. Accordingly, maternal COVID-19 impact to

either embryo or foetus is also not known. It is important to obtain long term follow-up on women who were pregnant at or around the time of vaccination so that any potential negative consequences to the pregnancy can be assessed and weighed against the effects of maternal COVID-19 on the pregnancy.

**Missing Information: Use in immunocompromised patients**

Risk-benefit impact

The safety profile of the vaccine is not known in immunocompromised individuals due to their exclusion from the pivotal clinical study. The efficacy of the vaccine may be lower in immunocompromised individuals, thus decreasing their protection from COVID-19.

**Missing Information: Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)**

Risk-benefit impact

There is limited information on the safety of the vaccine in frail patients with co-morbidities who are potentially at higher risk of severe COVID-19.

**Missing Information: Use in patients with autoimmune or inflammatory disorders**

Risk-benefit impact

There is limited information on the safety of the vaccine in individuals with autoimmune or inflammatory disorders and a theoretical concern that the vaccine may exacerbate their underlying disease.

**Missing Information: Interaction with other vaccines**

Risk-benefit impact

BNT162b2 mRNA vaccine will be used in individuals who also may receive other vaccines. Studies to determine if co-administration of BNT162b2 mRNA vaccine with other vaccines may affect the efficacy or safety of either vaccine have not been performed.

**Missing Information: Long term safety data**

Risk-benefit impact

The long-term safety of BNT162b2 mRNA vaccine is unknown at present, however further safety data are being collected in ongoing Study C4591001 for up to 2 years following administration of dose 2 of BNT162b2 mRNA vaccine.

## SVII.2. New Safety Concerns and Reclassification with a Submission of an Updated RMP

Not applicable.

## SVII.3. Details of Important Identified Risks, Important Potential Risks, and Missing Information

### SVII.3.1. Presentation of Important Identified Risks and Important Potential Risks

#### SVII.3.1.1. Important Identified Risk: Anaphylaxis

**Table 18. Anaphylaxis**

<b>Potential mechanisms, evidence source and strength of evidence</b>	Interaction of an allergen with IgE on basophils and mast cells triggers release of histamine, leukotrienes and other mediators that cause diffuse smooth muscle contraction and vasodilation with plasma leakage. This can manifest clinically with dyspnea, hypotension, swelling (sometimes leading to airway compromise), and rash (including hives).
<b>Characterisation of the risk</b>	Data from the ongoing Phase 3 clinical Study C4591001 have been reviewed and information pertinent to anaphylactic reactions observed in the study is summarized below.  Data from the CT database: 2 serious events (Anaphylactic reaction and Anaphylactic shock) were reported. Anaphylactic reaction due to a bee sting in a BNT162b2 recipient, and Anaphylactic shock due to an ant bite in a placebo recipient; both events were deemed not related to study treatment by the Investigator.  Data from the safety database: 2 serious events (Anaphylactic reaction and Anaphylactoid reaction) were reported during the emergency use authorization.
<b>Risk factors and risk groups</b>	Known hypersensitivity to any components of the vaccine.
<b>Preventability</b>	Prevention of anaphylaxis may not be possible, particularly with the 1st dose of a vaccine; therefore, healthcare professionals administering the vaccine must be vigilant for early signs and symptoms.
<b>Impact on the risk-benefit balance of the biologic product</b>	Anaphylactic reaction in an individual can be impactful (medically important) because it is a potentially life-threatening event requiring medical intervention.
<b>Public health impact</b>	Minimal due to rarity of the event. Although the potential clinical consequences of an anaphylactic reaction are severe, this is a known risk of vaccines to healthcare professionals with negligible public health impact. Almost 22,000 subjects were exposed to BNT162b2 in the clinical studies and no events of vaccine-related anaphylaxis were observed. It is unknown how many events will be observed in the post-marketing setting but expected to be very rare.

**SVII.3.1.2. Important Potential Risk: Vaccine-Associated Enhanced Disease (VAED), including Vaccine-Associated Enhanced Respiratory Disease (VAERD)**

**Table 19. Vaccine-Associated Enhanced Disease (VAED), including Vaccine-Associated Enhanced Respiratory Disease (VAERD)**

<p><b>Potential mechanisms, evidence source and strength of evidence</b></p>	<p>This potential risk is theoretical because it has not been described in association with the COVID-19 mRNA vaccine or it has not been reported from any other late phase clinical trial of other human vaccine. Animal models of SARS-CoV-2 infection have not shown evidence of VAED after immunization, whereas cellular immunopathology has been demonstrated after viral challenge in some animal models administered SARS-CoV-1 (murine, ferret and non-human primate models) or MERS-CoV (mice model) vaccines.<sup>25,33</sup> This potential risk has been included based on these animal data with these related betacoronaviruses. Historically, disease enhancement in vaccinated children following infection with natural virus has been observed with an inactivated respiratory syncytial virus vaccine.<sup>34</sup></p> <p>Potential mechanisms of enhanced disease may include both T cell-mediated [an immunopathological response favouring T helper cell type 2 (T<sub>H</sub>2) over T helper cell type 1 (T<sub>H</sub>1)] and antibody-mediated immune responses (antibody responses with insufficient neutralizing activity leading to formation of immune complexes and activation of complement or allowing for Fc-mediated increase in viral entry to cells).<sup>35</sup></p>																																																	
<p><b>Characterisation of the risk</b></p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="5" style="text-align: center;"><b>Confirmed Case of Postvaccination Severe COVID-19 – Safety Population (C4591001)</b></th> </tr> <tr> <th rowspan="2" style="text-align: center;"><b>Timing</b></th> <th colspan="2" style="text-align: center;"><b>BNT162b2 (30 µg) (N<sup>a</sup>=21721)</b></th> <th colspan="2" style="text-align: center;"><b>Placebo (N<sup>a</sup>=21729)</b></th> </tr> <tr> <th style="text-align: center;"><b>n<sup>b</sup> (%)</b></th> <th style="text-align: center;"><b>(95% CI<sup>c</sup>)</b></th> <th style="text-align: center;"><b>n<sup>b</sup> (%)</b></th> <th style="text-align: center;"><b>(95% CI<sup>c</sup>)</b></th> </tr> </thead> <tbody> <tr> <td>PD1 Before Dose 2</td> <td style="text-align: center;">0</td> <td style="text-align: center;">(0.0, 0.0)</td> <td style="text-align: center;">4 (0.0)</td> <td style="text-align: center;">(0.0, 0.0)</td> </tr> <tr> <td style="padding-left: 20px;">Within 7 days PD1</td> <td style="text-align: center;">0</td> <td style="text-align: center;">(0.0, 0.0)</td> <td style="text-align: center;">0</td> <td style="text-align: center;">(0.0, 0.0)</td> </tr> <tr> <td style="padding-left: 20px;">Within 14 days PD1</td> <td style="text-align: center;">0</td> <td style="text-align: center;">(0.0, 0.0)</td> <td style="text-align: center;">3 (0.0)</td> <td style="text-align: center;">(0.0, 0.0)</td> </tr> <tr> <td>PD2</td> <td style="text-align: center;">1 (0.0)</td> <td style="text-align: center;">(0.0, 0.0)</td> <td style="text-align: center;">5 (0.0)</td> <td style="text-align: center;">(0.0, 0.1)</td> </tr> <tr> <td style="padding-left: 20px;">Within 7 days PD2</td> <td style="text-align: center;">0</td> <td style="text-align: center;">(0.0, 0.0)</td> <td style="text-align: center;">1 (0.0)</td> <td style="text-align: center;">(0.0, 0.0)</td> </tr> <tr> <td style="padding-left: 20px;">Within 14 days PD2</td> <td style="text-align: center;">0</td> <td style="text-align: center;">(0.0, 0.0)</td> <td style="text-align: center;">2 (0.0)</td> <td style="text-align: center;">(0.0, 0.0)</td> </tr> <tr> <td><b>Total<sup>d</sup></b></td> <td style="text-align: center;"><b>1 (0.0)</b></td> <td style="text-align: center;"><b>(0.0, 0.0)</b></td> <td style="text-align: center;"><b>9 (0.0)</b></td> <td style="text-align: center;"><b>(0.0, 0.1)</b></td> </tr> </tbody> </table> <p>Note: This table includes subjects from Phase 2/3 only. Abbreviations: PD1 = post-dose 1; PD2 = post-dose 2. a. N = number of subjects in the specified group. This value is the denominator for the percentage calculations. b. n = Number of subjects reporting at least 1 occurrence of the specified event. c. Exact 2-sided CI based on the Clopper and Pearson method. d. Total is the sum of PD1 and PD2.</p> <p>PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (10:49) Source Data: adc19ef Table Generation: 19NOV2020 (00:22) (Cutoff date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: (CDISC)/C4591001_RMP_Phase1_2_3/adeff_s901</p> <p>If VAED/VAERD were to occur in vaccinated individuals, it may manifest as a modified and/or more severe clinical presentation of SARS-CoV-2 viral infection upon subsequent natural infection. This may result in individuals assumed to be at lower risk for severe COVID-19 having more severe disease, for individuals at</p>	<b>Confirmed Case of Postvaccination Severe COVID-19 – Safety Population (C4591001)</b>					<b>Timing</b>	<b>BNT162b2 (30 µg) (N<sup>a</sup>=21721)</b>		<b>Placebo (N<sup>a</sup>=21729)</b>		<b>n<sup>b</sup> (%)</b>	<b>(95% CI<sup>c</sup>)</b>	<b>n<sup>b</sup> (%)</b>	<b>(95% CI<sup>c</sup>)</b>	PD1 Before Dose 2	0	(0.0, 0.0)	4 (0.0)	(0.0, 0.0)	Within 7 days PD1	0	(0.0, 0.0)	0	(0.0, 0.0)	Within 14 days PD1	0	(0.0, 0.0)	3 (0.0)	(0.0, 0.0)	PD2	1 (0.0)	(0.0, 0.0)	5 (0.0)	(0.0, 0.1)	Within 7 days PD2	0	(0.0, 0.0)	1 (0.0)	(0.0, 0.0)	Within 14 days PD2	0	(0.0, 0.0)	2 (0.0)	(0.0, 0.0)	<b>Total<sup>d</sup></b>	<b>1 (0.0)</b>	<b>(0.0, 0.0)</b>	<b>9 (0.0)</b>	<b>(0.0, 0.1)</b>
<b>Confirmed Case of Postvaccination Severe COVID-19 – Safety Population (C4591001)</b>																																																		
<b>Timing</b>	<b>BNT162b2 (30 µg) (N<sup>a</sup>=21721)</b>		<b>Placebo (N<sup>a</sup>=21729)</b>																																															
	<b>n<sup>b</sup> (%)</b>	<b>(95% CI<sup>c</sup>)</b>	<b>n<sup>b</sup> (%)</b>	<b>(95% CI<sup>c</sup>)</b>																																														
PD1 Before Dose 2	0	(0.0, 0.0)	4 (0.0)	(0.0, 0.0)																																														
Within 7 days PD1	0	(0.0, 0.0)	0	(0.0, 0.0)																																														
Within 14 days PD1	0	(0.0, 0.0)	3 (0.0)	(0.0, 0.0)																																														
PD2	1 (0.0)	(0.0, 0.0)	5 (0.0)	(0.0, 0.1)																																														
Within 7 days PD2	0	(0.0, 0.0)	1 (0.0)	(0.0, 0.0)																																														
Within 14 days PD2	0	(0.0, 0.0)	2 (0.0)	(0.0, 0.0)																																														
<b>Total<sup>d</sup></b>	<b>1 (0.0)</b>	<b>(0.0, 0.0)</b>	<b>9 (0.0)</b>	<b>(0.0, 0.1)</b>																																														

**Table 19. Vaccine-Associated Enhanced Disease (VAED), including Vaccine-Associated Enhanced Respiratory Disease (VAERD)**

	known risk for severe COVID-19 (e.g. older or immunocompromised) having higher rates of fatal outcomes, or for observation of an unfavourable imbalance in severe COVID-19 cases in vaccinated individuals when compared to those not vaccinated. It is challenging if not impossible to assess for VAED/VAERD on an individual case basis, given the lack of specific clinical or laboratory markers at this time, rather surveillance for this theoretical risk needs to be at a population level, <sup>36</sup> as noted above. The table above shows a favourable balance of severe COVID-19 cases in participants receiving COVID-19 mRNA vaccine versus those receiving placebo, providing reassurance against the potential risk of VAED/VAERD at this time.
<b>Risk factors and risk groups</b>	It is postulated that the potential risk may be increased in individuals producing lower neutralizing antibody titers or in those demonstrating waning immunity. <sup>35,36</sup>
<b>Preventability</b>	An effective vaccine against COVID-19 that produces high neutralizing titers and a T <sub>H</sub> 1 predominant CD4 <sup>+</sup> T cell response and strong CD8 <sup>+</sup> T cell response, is expected to mitigate the risk of VAED/VAERD; <sup>25,35</sup> that immune profile is elicited by BNT162b2 in clinical and preclinical studies. <sup>37,38</sup>
<b>Impact on the risk-benefit balance of the biologic product</b>	If there were an unfavourable balance in COVID-19 cases, including severe cases, in the pivotal clinical study between the vaccine and placebo groups, that may signal VAED/VAERD.
<b>Public health impact</b>	The potential risk of VAED/VAERD could have a public health impact if large populations of individuals are affected.

### SVII.3.2. Presentation of the Missing Information

**Table 20. Use in pregnancy and while breast feeding**

<p><u>Evidence source:</u> The safety profile of the vaccine is not known in pregnant or breastfeeding women due to their exclusion from the pivotal clinical study. There may be pregnant women who choose to be vaccinated despite the lack of safety data. It will be important to follow these women for pregnancy and birth outcomes. The timing of vaccination in a pregnant woman and the subsequent immune response may have varying favourable or unfavourable impacts on the embryo/foetus. The clinical consequences of SARS-CoV-2 infection to the woman and foetus during pregnancy is not yet fully understood and the pregnant woman's baseline health status may affect both the clinical course of her pregnancy and the severity of COVID-19. These factors and the extent to which the pregnant woman may be at risk of exposure to SARS-CoV-2 will influence the benefit risk considerations for use of the vaccine.</p> <p><u>Population in need of further characterization:</u> The lack of data will be communicated in product labelling; clinical study of the safety and immunogenicity of COVID-19 mRNA vaccine in pregnant women, is planned.</p>
--

**Table 21. Use in immunocompromised patients**

Evidence source:

The vaccine has not been studied in individuals with overt immunocompromised conditions. Therefore, further safety data will be sought in this population.

Population in need of further characterisation:

Safety data will be collected in individuals with compromised immune function due to acquired or genetic conditions or conditions requiring the use of immunosuppressants as this population of individuals in the active surveillance studies and the clinical studies proposed by the MAA (see [Section PART III](#)).

**Table 22. Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)**

Evidence source:

The vaccine has been studied in individuals with stable chronic diseases (e.g. hypertension, obesity), however it has not been studied in frail individuals with severe co-morbidities that may compromise immune function due to the condition or treatment of the condition. Therefore, further safety data will be sought in this population.

Population in need of further characterisation:

Safety data will be collected in individuals who are frail due to age or debilitating disease in the active surveillance studies and through routine pharmacovigilance.

**Table 23. Use in patients with autoimmune or inflammatory disorders**

Evidence source:

There is limited information on the safety of the vaccine in patients with autoimmune or inflammatory disorders.

Population in need of further characterisation:

Safety data will be collected in individuals with autoimmune or chronic inflammatory diseases, including those who may be on immunosuppressants in the active surveillance studies.

**Table 24. Interaction with other vaccines**

Evidence source:

There are no data on interaction of BNT162b2 mRNA vaccine with other vaccines at this time.

Population in need of further characterisation:

All reports describing interactions of COVID-19 vaccine with other vaccines per national recommendations in individuals will be collected and analysed as per routine PV activities. Interactions with commonly used non-COVID-19 vaccines, such as influenza vaccine, are proposed to be studied in a future clinical study.



**Table 25. Long term safety data**

Evidence source:

At this time, 2-month post dose 2 safety data are available for approximately half of the patients who have received BNT162b2 mRNA vaccine in Study C4591001. The study is ongoing.

Anticipated risk/consequence of missing information:

At the time of vaccine availability, the long-term safety of BNT162b2 mRNA vaccine is not fully known, however there are no known risks with a potentially late onset. Data will continue to be collected from participants in ongoing study C4591001 for up to 2 years following the 2<sup>nd</sup> dose of vaccine. Additionally, active surveillance studies are planned to follow long-term safety in vaccine recipients for 2 years following Dose 2.

**Module SVIII. Summary of the Safety Concerns**

**Table 26. Summary of Safety Concerns**

Important Identified Risks	Anaphylaxis
Important Potential Risks	Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)
Missing Information	Use in pregnancy and while breast feeding
	Use in immunocompromised patients
	Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)
	Use in patients with autoimmune or inflammatory disorders
	Interaction with other vaccines
	Long term safety data

## **PART III. PHARMACOVIGILANCE PLAN (INCLUDING POST-AUTHORISATION SAFETY STUDIES)**

### **III.1. Routine Pharmacovigilance Activities**

Routine pharmacovigilance for the lifecycle of a product is a critical component to the detection, assessment, understanding and mitigation of AEs. Objectives of routine pharmacovigilance includes having processes in place to assure the ongoing and timely collection, processing, follow-up, and analysis of individual AE reports and aggregate data globally, following global safety Standard Operating Procedures and regulatory guidance.

Pfizer, on behalf of the MAA monitors the safety profile of its products, evaluates issues potentially impacting product benefit-risk profiles in a timely manner, and ensures that appropriate communication of relevant safety information is conveyed in a timely manner to regulatory authorities and other interested parties as appropriate and in accordance with international principles and prevailing regulations. Pfizer, on behalf of the MAA, gathers data for signal detection and evaluation commensurate with product characteristics.

Routine pharmacovigilance activities beyond the receipt and review of individual AE reports (e.g. ADRs) include:

- Data Capture Aids have been created for this vaccine. They are intended to facilitate the capture of clinical details about
  - the nature and severity of COVID-19 illness in individuals who have received the COVID-19 mRNA vaccine and is anticipated to provide insight into potential cases of vaccine lack of effect or VAED. The DCA is provided in [Annex 4](#);
  - potential anaphylactic reactions in individuals who have received the COVID-19 mRNA vaccine. This DCA is in preparation and will be submitted.
- Signal detection activities for the lifecycle of vaccines consist of individual AE assessment at case receipt, regular aggregate review of cases for trends and statistically disproportionately reported product-adverse event pairs. Aggregated and statistical reviews of data are conducted utilizing Pfizer’s software interactive tools. Safety signal evaluation requires the collection, analysis and assessment of information to evaluate potential causal associations between an event and the product and includes subsequent qualitative or quantitative characterization of the relevant safety risk to determine appropriate continued pharmacovigilance and risk mitigation actions. Signal detection activities for the COVID-19 mRNA vaccine, will occur on a weekly basis. In addition, observed versus expected analyses will be conducted as appropriate as part of routine signal management activity.
- Routine signal detection activities for the COVID-19 mRNA vaccine will include routine and specific review of AEs consistent with the AESI list provided in [PART II.SVII.1.1 – Risks not considered important for inclusion in the list of safety concerns in the RMP](#).
- In addition, published literature is reviewed weekly for individual case reports and broader signal detection purposes.

- Regulatory authority safety alerts monitoring.
- A web-based AE reporting portal will be available for vaccine providers (e.g. pharmacists, nurses, physicians and others who administer vaccines) and recipients, to assist with anticipated high volume of reports (based on expectations of a large target population for vaccination). The portal will capture key adverse event data in the initial interaction and will provide automated intake into the Pfizer safety database via E2B for safety review.
- At the country level, the Pfizer Drug Safety Units perform routine pharmacovigilance activities including the collection of AEs from various sources and the reporting of AEs to the regulatory authority as per local regulatory guidelines.
- The serious adverse event (SAE)/product complaint (PC) Joint Report for Sterile Injectables is run monthly. In addition, the AE/PC Joint report and the AE/PC Lot/Lot profile Report is run quarterly and is a statistical report that identifies any data that could constitute a safety signal over time. The AE/PC Lot/Lot Profile report complements the monthly AE trending performed by Safety and the monthly PC trending performed by Product Quality.

### **Monthly summary safety reports**

In addition to routine 6-monthly PSUR production, monthly summary safety reports will be compiled to support timely and continuous benefit risk evaluations. Topics covered by monthly summary safety reports will include:

- Interval and cumulative number of reports, stratified by report type (medically confirmed/not) and by seriousness (including fatal separately);
- Interval and cumulative number of reports, overall and by age groups and in special populations (e.g. pregnant women);
- Interval and cumulative number of reports per HLT and SOC;
- Summary of the designated medical events;
- Reports per EU country;
- Exposure data (including age-stratified);
- Changes to reference safety information in the interval, and current CCDS;
- Ongoing and closed signals in the interval;
- AESI reports – numbers and relevant cases;
- Fatal reports – numbers and relevant cases;
- Risk/benefit considerations.

The submission of monthly reports complements the submission of 6 monthly PSURs. The need and frequency of submission of such reports will be re-evaluated based on the available evidence from post-marketing after 6 months (6 submissions).

- Monthly reports and PSURs will include results of the observed versus expected analysis for AESI as appropriate, including cases of Bell's palsy and will present the results and details of the statistical approach.

## Potential Medication Errors

Large scale public health approaches for mass vaccination may represent changes to standard vaccine treatment process, thereby potentially introducing the risk of medication errors related to: reconstitution and administration, vaccination scheme, storage conditions, errors associated with a multi-dose vial, and once other COVID vaccines are available, confusion with other COVID vaccines. These potential medication errors are mitigated through the information in the SmPC and available educational materials for healthcare providers.

- SmPC (section 6.6) contains instructions for reconstitution and administration, vaccination scheme, and storage conditions of the COVID-19 mRNA vaccine.
- A poster with step-by-step instruction for vaccine storage, dose planning and preparation, and administration is available, which can be conspicuously displayed in settings where vaccine is to be administered for ongoing reference.
- Brochures for safe handling of the vaccine and dry ice will accompany vaccine shipments.
- Medical information call centers will be available for healthcare providers to obtain information on use of the vaccine.
- Traceability and Vaccination Reminder card ([Annex 7](#)) will be provided with the pre-printed manufacturer name, placeholder spaces for dates of vaccinations and batch/lot numbers as a mitigation effort for potential confusion between vaccines. (see Traceability for additional details).

These available resources will inform healthcare providers on the proper preparation and administration of the vaccine and reduce the potential for medication error in the context of a mass vaccination campaign. Additionally, the patient information leaflet and Traceability and Vaccination Reminder card informs patients of the vaccine received so that a series is completed with the same product.

## Traceability

The SmPC, includes instructions for healthcare professionals:

- to clearly record the name and batch number of the administered vaccine to improve traceability (section 4.4);
- to report any suspected adverse reactions including batch/Lot number if available (section 4.8).

Traceability is available for every shipping container of COVID mRNA vaccine, which are outfitted with a unique device that provides real-time monitoring of geographic location and temperature 24 hours per day, 7 days per week. Each device will also trace the batch/lot of the associated shipment. The device is activated prior to shipment and information is transmitted wirelessly to Pfizer at a predefined cadence, on behalf of the MAA, until delivery to the vaccinator's practice site. A shipment quality report that indicates if the product is acceptable for immediate use is generated by Pfizer on behalf of the MAA and transmitted to

the vaccinator's practice site upon pressing of the stop button on the data logger, or arrival notification from the carrier in combination with the data loggers location and/or light signal. Additionally, alarms and escalation/notification for excursions (per pre-defined specifications) are programmed into the device. These data may be used for the assessment of a safety signal.

The vaccine carton labelling also contains a 2-D barcode which has the batch/lot and expiry embedded within, should there be capability at a vaccination site to utilize this as an information source.

Further, Pfizer on behalf of the MAA, will make available Traceability and Vaccination Reminder cards ([Annex 7](#)) to vaccinators that may be completed at the time of vaccination. The Traceability and Vaccination Reminder cards contain the following elements:

- Placeholder space for name of vaccinee;
- Vaccine brand name and manufacturer name;
- Placeholder space for due date and actual date of first and second doses, and associated batch/lot number;
- Reminder to retain the card and bring to the appointment for the second dose of the vaccine;
- QR code that links to additional information; and
- Adverse event reporting information.

In addition, to the Traceability and Vaccination Reminder cards, two stickers per dose, containing printed batch/lot information, will be made available to support documentation of the batch/lot on the Traceability and Vaccination Reminder card and vaccinee medical records in mass vaccination centers. We also acknowledge that some EU member states may require utilization of nationally mandated vaccination cards or electronic systems to document batch/lot number; therefore, the available Traceability and Vaccination Reminder cards and stickers with printed lot/batch information may not be utilized in all member states. The following milestones are proposed for the availability of the stickers with printed lot/batch information:

- Initial vaccine availability: Sufficient quantities of blank "Traceability and Vaccination Reminder cards" will be made available to vaccinators in the member states where utilization of a nationally mandated vaccination card is not required.
- 31 January 2021: In addition to the blank "Traceability and Vaccination Reminder cards", stickers with printed lot/batch information will be made available to vaccinators at large scale (1000 subjects/day), mass vaccination sites in the member states where the national authority has not mandated another mechanism for documenting the lot/batch information.
- Projected 2022: Upon development and approval of single-dose vials, pre-printed batch/lot stickers will be available to co-ship with each vaccine shipment.

## **Cold-Chain Handling and Storage**

Multiple modalities will be utilized for quality assurance throughout shipment due to the required ultra-cold storage for COVID-19 mRNA vaccine.

- Each shipment of the vaccine is outfitted with a unique device that provides real-time monitoring of geographic location and temperature 24 hours per day, 7 days per week until delivery to a vaccinator's practice site. Alarms and escalation/notification to Pfizer on behalf of the MAA and/or to the recipient for excursions (per pre-defined specifications) are programmed into the device. Additionally, a shipment quality report that indicates if the product is acceptable for immediate use is generated by Pfizer and transmitted to the vaccinator's practice site.
- Joint adverse event and product complaint (including available batch/lot information) trending reviews occur routinely with Global Product Quality.
- Additionally, available educational materials for vaccinators will include information regarding proper handling of the shipment container as temporary storage, and handling/disposal of dry ice until the received shipment is either placed into an ultra-low temperature freezer, or is maintained in accord with pre-defined specifications in the shipment container as temporary storage (i.e. upon receipt of the shipment quality report noted above), as appropriate.

### III.2. Additional Pharmacovigilance Activities

The MAA proposes the following 11 studies, of which 1 global, 3 in Europe only, 2 in Europe and US, and 3 in US only; the countries where 2 studies will be conducted are not available at this time. There are 6 Interventional studies (C4591001, C4591015, BNT162-01 Cohort 13, C4591018, 1 study in high risk adults and 1 study for vaccine interactions ) and 5 Non-Interventional studies (4 safety and 1 effectiveness), summarized in the table below and further detailed in [Table 27](#) and [Table 28](#).

Study Number	Country	Interventional/ Non-Interventional	Purpose
C4591001	Global	Interventional	Safety
C4591015	Not available at this time	Interventional	Safety
C4591010	EU	Non-Interventional	Safety
C4591011	US	Non-Interventional	Safety
C4591012	US	Non-Interventional	Safety
ACCESS/VAC4EU	EU	Non-Interventional	Safety
C4591014	EU, US	Non-Interventional	Effectiveness <sup>a</sup>
BNT162-01 Cohort 13	EU	Interventional	Safety
C4591018	US	Interventional	Safety
Safety and immunogenicity in high risk adults <sup>b</sup>	EU, US	Interventional	Safety
Co-administration study with seasonal influenza vaccine	Not available at this time	Interventional	Safety

a. Vaccine effectiveness is not a safety concern;

b. On review of preliminary information from BNT162-01 cohort 13, C4591001 HIV-infected and high-risk populations and C4591018, a further safety and immunogenicity study is anticipated in up to 150 adult subjects with a range of primary immunocompromising conditions and/or receiving immunocompromising treatments or in conditions.

#### *Non-Interventional Post Approval Safety Studies (4)*

- The MAA proposes 4 complementary studies of real-world safety of COVID-19 mRNA vaccine that use multiple data sources and study designs. These are described in [Table 27](#) below which includes the proposed post-approval safety studies that will be conducted in the EU and US.
- Study C4591010 will be conducted in the EU using primary data collection to monitor a cohort of vaccinees and evaluate risk of safety events of interest reflecting the AESI list. A draft protocol C4591010 is provided in [Annex 2](#).
- Additionally, Pfizer, on behalf of the MAA, will sponsor one or more PASS using secondary EHR data sources in Europe based on a master surveillance protocol developed through the ACCESS project, which is funded by EMA and conducted via the Vaccine monitoring Collaboration for Europe (VAC4EU) (VAC4EU, 2020). The MAA has initiated a request for proposal with the VAC4EU secretariat. Pfizer on behalf of the MAA, understands that the master protocol is under development with the EMA and



notification will be provided once finalized and will provide draft protocols as soon as available.

- In addition to the studies planned for EU, in support of the US EUA application, Pfizer has submitted to the FDA 2 draft protocols for safety surveillance of COVID-19 mRNA vaccine in populations expected to receive the vaccination under EUA in the US. These studies include:
  - 1 study using secondary data from EHR of active military and their families (C4591011),
  - 1 study using secondary data from EHR of patients included in the Veterans Healthcare Administration system (C4591012).
- The draft protocols for the proposed safety studies in the US (C4591011 and C4591012) are included in [Annex 2](#).

#### *Non-Interventional Post-Approval Safety Studies in Pregnancy*

The proposed strategy to assess vaccination during pregnancy will be implemented in 2 stages. It is anticipated that initial use in pregnancy will be subject to local health authority recommendations regarding which individuals should be vaccinated and likely very limited intentional vaccination of pregnant women; therefore, initially this information will derive from 3 of the real-world safety studies (C4591010, C4591011, and ACCESS/VAC4EU), described in [Table 27](#). Study C4591012 is focused on patients in the Veterans Health Administration system and is not expected to capture many pregnancies given the demographics of the source population. The findings from studies' interim analysis (where planned) will inform a strategy to assess pregnancy outcomes as vaccination in pregnancy expands. MAA will consider established EU pregnancy research recommendations such as CONSIGN (COVID-19 infectiOn aNd medicineS In pregnancy) when developing any pregnancy related study objectives (currently not listed in [Table 27](#) and [Table 28](#)).

The MAA agrees that monitoring vaccine safety in pregnant women is critical. Given that a pregnancy registry based on primary data collection is susceptible to non-participation, attrition, small sample size and limited or lack of comparator data, Pfizer, on behalf of the MAA, would like to propose monitoring vaccine safety in pregnancy using electronic health care data, which could be conducted in a representative pregnant woman population exposed to the vaccine and minimize selection bias, follow-up bias, and reporting bias. In addition, internal comparison groups, such as contemporaneous unvaccinated pregnant women or women receiving other vaccine(s) to prevent COVID-19 (if available) could be included.

#### *Non-Interventional Post-Approval Effectiveness (1)*

Pfizer will conduct, on behalf of the MAA, at least one non-interventional study (test negative design) of individuals presenting to the hospital or emergency room with symptoms of potential COVID-19 illness in a real-world setting (C4591014). The effectiveness of COVID-19 mRNA vaccine will be estimated against laboratory confirmed COVID 19 illness

requiring admission to the Emergency Department (ED) or hospital where SARS-CoV-2 is identified. These studies will allow to determine the effectiveness of Pfizer's vaccine in a real-world setting and against severe disease, and in specific racial, ethnic, and age groups. The studies proposed below are under evaluation as potential commitments; studies are presented by geographical area (US and EU).

**Table 27. Additional Pharmacovigilance Activities**

Study Number <i>Country (ies)</i>	Study Title  Study Type <i>Study Status</i>	Rationale and Study Objectives	Study design	Study populations	Milestones	
C4591001  Global	A Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-COV-2 RNA vaccine candidates against COVID-19 in healthy individuals  Interventional <i>Ongoing</i>	The objective of the study is to evaluate the safety, tolerability, immunogenicity and efficacy of COVID-19 mRNA vaccine  An unfavorable imbalance between the vaccine and control groups in the frequency of COVID-19, in particular for severe COVID-19, may suggest the occurrence of vaccine associated enhanced disease. Surveillance is planned for 2 years following Dose 2	Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.	Healthy men and women 18-55 and 65-85 years of age. Male and female, aged ≥ 12 years of age. Stable chronic conditions including stable treated HIV, HBV and HCV allowed, excluding immunocompromising conditions and treatments.	CSR submission upon regulatory request:	Any time
					CSR submission 6 months post Dose 2:	31-Dec-2021
					Final CSR submission with supplemental follow-up:	31-Aug-2023

**Table 27. Additional Pharmacovigilance Activities**

Study Number <i>Country (ies)</i>	Study Title  Study Type Study Status	Rationale and Study Objectives	Study design	Study populations	Milestones	
C4591011  US	Safety Surveillance of the Pfizer COVID-19 Vaccine in the U.S. Department of Defense Population Following Emergency Use Authorization  Non-Interventional <i>Planned</i>	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in a cohort of people within the Department of Defense Healthcare System.	Secondary database analysis of observational data to estimate incidence rates of safety events of interest and other clinically significant events in a cohort of active military and their families who receive the COVID-19 mRNA vaccine under EUA in the US	Active military and their families	Interim reports submission:	30-Jun-2021
						31-Dec-2021
						30-Jun-2022
					31-Dec-2022	
Final CSR submission:	31-Dec-2023					
C4591012  US	Post-Emergency Use Authorization Active Surveillance of Adverse Events of Special Interest among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine  Non-Interventional <i>Planned</i>	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine.	Secondary database analysis of observational data to estimate incidence rates of safety events of interest and other clinically significant events in a cohort of US veterans who receive the COVID-19 mRNA vaccine under EUA in the US	US Veteran's	Interim reports submission:	30-Jun-2021
						31-Dec-2021
						30-Jun-2022
					31-Dec-2022	
Final CSR submission:	31-Dec-2023					

**Table 27. Additional Pharmacovigilance Activities**

Study Number <i>Country (ies)</i>	Study Title  Study Type Study Status	Rationale and Study Objectives	Study design	Study populations	Milestones	
C4591010  EU	A Post-Approval Active Surveillance Safety Study to Monitor Real-World Safety of the Pfizer-BioNTech COVID-19 vaccine in the EU  Non-Interventional <i>Planned</i>	Assessment of occurrence of safety events in real-world use of COVID-19 mRNA vaccine.	Primary data collection cohort study	EU general population	Final draft protocol submission for EMA review:	31-Jan-2021
					Final CSR submission:	31-Mar-2024
C4591015  Not available	A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older  Interventional <i>Planned</i>	Planned clinical study to assess safety and immunogenicity in pregnant women who receive COVID-19 mRNA vaccine Safety and immunogenicity of COVID-19 mRNA vaccine in pregnant women	Randomized, placebo-controlled, observer-blind study	Healthy pregnant women 18 years of age or older vaccinated during their 24 to 34 weeks of gestation	Protocol draft submission:	28-Feb-2021
					Final CSR submission:	30-Apr-2023

**Table 27. Additional Pharmacovigilance Activities**

Study Number <i>Country (ies)</i>	Study Title  Study Type <i>Study Status</i>	Rationale and Study Objectives	Study design	Study populations	Milestones	
C4591014  EU, US	A test-negative design to evaluate the effectiveness of BNT162b2 against acute respiratory illness due to SARS-CoV-2 infection among adults ≥18 years of age  Non-Interventional <i>Planned</i>	Estimate the effectiveness of 2 doses of COVID-19 mRNA vaccine against potential COVID-19 illness requiring admission to the ED or hospital where SARS-CoV-2 is identified	Non-interventional study (test-negative design) of individuals presenting with symptoms of potential COVID-19 illness in a real-world setting	Adult individuals ≥18 years of age with acute respiratory infection admitted to the emergency department or hospital	Protocol draft submission:	31-Mar-2021
					Final CSR submission:	30-Jun-2023
BNT162-01 Cohort 13  EU	Immunogenicity of COVID-19 mRNA vaccine in immunocompromised subjects, including assessment of antibody responses and cell-mediated responses  Interventional <i>Ongoing</i>	To assess potentially protective immune responses in immunocompromised adults	Dose escalating Open uncontrolled	Use in immunocompromised patients	IA submission:	30-Sep-2021
					Final CSR submission:	31-Dec-2022
C4591018  US	Phase II study of BNT162b2 in adults receiving immunomodulators for rheumatoid arthritis (RA)  Interventional <i>Planned</i>	Safety, immunogenicity over 12 months. Description of COVID-19 cases. RA activity by Clinical Disease Activity Index. N-antigen antibodies for detection of asymptomatic infection.	Open uncontrolled	Immunocompromised adults with autoimmune disease (rheumatoid arthritis)	Protocol submission:	28-Feb-2021
					IA submission:	31-Dec-2021

**Table 27. Additional Pharmacovigilance Activities**

Study Number <i>Country (ies)</i>	Study Title  Study Type <i>Study Status</i>	Rationale and Study Objectives	Study design	Study populations	Milestones	
Safety and immunogenicity in high risk adults US, EU	Phase II study in high risk adults  Interventional <i>Planned</i>	Safety, immunogenicity over 12 months in frail elderly, immunocompromised, autoimmune and other high-risk individuals. Description of COVID-19 cases. N-antigen antibodies for detection of asymptomatic infection.	Open uncontrolled	High risk adults including frail elderly, those having autoimmune disease, chronic renal disease and immunocompromising conditions	Protocol submission:	30-Jun-2021
					Final CSR submission:	31-Dec-2022
ACCESS/VAC4EU EU	A Post-Approval Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of the Pfizer-BioNTech COVID-19 vaccine in the EU  Non-Interventional <i>Planned</i>	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine.	Secondary database analysis of observational data to estimate incidence rates of safety events of interest and other clinically significant events in cohorts of COVID-19 vaccine recipients in the EU	General population	Protocol submission:	28-Feb-2021
					Final CSR submission:	31-Jan- 2024
Co-administration study with seasonal influenza vaccine  Not available	Co-administration of BNT162b2 with seasonal influenza vaccine  Interventional <i>Planned</i>	Safety and immunogenicity of BNT162b2 and quadrivalent seasonal influenza vaccine when administered separately or concomitantly.	Not available at this time	General population	Protocol submission:	30-Sep-2021
					Final CSR submission:	31-Dec-2022

### III.3. Summary Table of Additional Pharmacovigilance Activities

#### III.3.1. On-Going and Planned Additional Pharmacovigilance Activities

**Table 28. On-going and Planned Additional Pharmacovigilance Activities**

Study ( <i>study short name, and title</i> )  Status ( <i>planned/on-going</i> )	Country	Summary of Objectives	Safety concerns addressed	Milestone	Due dates
<b>Category 2</b>					
C4591001 <i>Ongoing</i>	Global	<p>The objective of the study is to evaluate the safety, tolerability, immunogenicity and efficacy of COVID-19 mRNA vaccine</p> <p>An unfavorable imbalance between the vaccine and control groups in the frequency of COVID-19, in particular for severe COVID-19, may suggest the occurrence of vaccine associated enhanced disease. Surveillance is planned for 2 years following Dose 2.</p>	<p>Anaphylaxis</p> <p>Vaccine-associated enhanced disease (VAED) including vaccine-associated enhanced respiratory disease (VAERD)</p> <p>Use in patients with co-morbidities (C4591001 subset)</p> <p>Long term safety data.</p>	<p>CSR submission upon regulatory request:</p> <p>CSR submission 6 months post Dose 2:</p> <p>Final CSR submission with supplemental follow-up:</p>	<p>Any time</p> <p>31-Dec-2021</p> <p>31-Aug-2023</p>



**Table 28. On-going and Planned Additional Pharmacovigilance Activities**

Study ( <i>study short name, and title</i> ) Status ( <i>planned/on-going</i> )	Country	Summary of Objectives	Safety concerns addressed	Milestone	Due dates
<b>Category 3</b>					
C4591011 <i>Planned</i>	US	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in a cohort of people within the Department of Defense Healthcare System.	Anaphylaxis AESI-based safety events of interest including vaccine associated enhanced disease Use in pregnancy Use in immunocompromised patients Use in frail patients with co-morbidities (e.g, chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders) Use in patients with autoimmune or inflammatory disorders Long-term safety data.	Interim reports submission:	30-Jun-2021
				31-Dec-2021	
				30-Jun-2022	
				31-Dec-2022	
				Final CSR submission:	31-Dec-2023
C4591012 <i>Planned</i>	US	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine.	Anaphylaxis AESI-based safety events of interest including vaccine associated enhanced disease Use in immunocompromised patients Use in frail patients with co-morbidities (e.g, chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders) Use in patients with autoimmune or inflammatory disorders Long-term safety data.	Interim reports submission:	30-Jun-2021
				31-Dec-2021	
				30-Jun-2022	
				31-Dec-2022	
				Final CSR submission:	31-Dec-2023

**Table 28. On-going and Planned Additional Pharmacovigilance Activities**

<b>Study (study short name, and title) Status (planned/on-going)</b>	<b>Country</b>	<b>Summary of Objectives</b>	<b>Safety concerns addressed</b>	<b>Milestone</b>	<b>Due dates</b>
C4591010 <i>Planned</i>	EU	Assessment of occurrence of safety events in real-world use of COVID-19 mRNA vaccine.	Anaphylaxis AESI-based safety events of interest Use in pregnancy Long-term safety data.	Final draft protocol submission for EMA review:	31-Jan-2021
				Final CSR submission:	31-Mar-2024
C4591015 <i>Planned</i>	Not available	Planned clinical study to assess safety and immunogenicity in pregnant women who receive COVID-19 mRNA vaccine  Safety and immunogenicity of COVID-19 mRNA vaccine in pregnant women	Use in pregnancy and while breast feeding.	Protocol draft submission:	28-Feb-2021
				Final CSR submission:	30-Apr-2023
C4591014 <i>Planned</i>	EU, US	Estimate the effectiveness of 2 doses of COVID-19 mRNA vaccine against potential COVID-19 illness requiring admission to the ED or hospital where SARS-CoV-2 is identified	Not Applicable.	Protocol draft submission:	31-Mar-2021
				Final CSR submission:	30-Jun-2023
BNT162-01 Cohort 13 <i>Ongoing</i>	EU	To assess potentially protective immune responses in immunocompromised adults	Use in immunocompromised patients.	IA submission:	30-Sep-2021
				Final CSR submission:	31-Dec-2022

**Table 28. On-going and Planned Additional Pharmacovigilance Activities**

<b>Study (study short name, and title) Status (planned/on-going)</b>	<b>Country</b>	<b>Summary of Objectives</b>	<b>Safety concerns addressed</b>	<b>Milestone</b>	<b>Due dates</b>
C4591018 <i>Planned</i>	US	Safety, immunogenicity over 12 months. Description of COVID-19 cases. RA activity by Clinical Disease Activity Index. N-antigen antibodies for detection of asymptomatic infection.	Use in immunocompromised patients Use in patient with autoimmune or inflammatory disorders.	Protocol submission:	28-Feb-2021
				IA submission:	31-Dec-2021
Safety and immunogenicity in high risk adults <i>Planned</i>	EU, US	Safety, immunogenicity over 12 months in frail elderly, immunocompromised, autoimmune and other high-risk individuals. Description of COVID-19 cases. N-antigen antibodies for detection of asymptomatic infection.	Use in frail patients with co-morbidities (e.g, chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders).	Protocol submission:	30-Jun-2021
				Final CSR submission:	31-Dec-2022
ACCESS/VAC4EU <i>Planned</i>	EU	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine.	Anaphylaxis AESI-based safety events of interest including vaccine associated enhanced disease Use in pregnancy Use in immunocompromised patients Use in frail patients with co-morbidities (e.g, chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders) Use in patients with autoimmune or inflammatory disorders Long term safety data.	Protocol submission:	28-Feb-2021
				Final CSR submission:	31-Jan-2024
Co-administration study with seasonal influenza vaccine <i>Planned</i>	Not available	Safety and immunogenicity of BNT162b2 and quadrivalent seasonal influenza vaccine when administered separately or concomitantly.	Interaction with other vaccines.	Protocol submission:	30-Sep-2021
				Final CSR submission:	31-Dec-2022

**PART IV. PLANS FOR POST AUTHORISATION EFFICACY STUDIES**

None.

**PART V. RISK MINIMISATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMISATION ACTIVITIES)**

**RISK MINIMISATION PLAN**

The safety information in the proposed product information is aligned to the reference medicinal product.

**V.1. Routine Risk Minimisation Measures**

The product information is sufficient to mitigate the current identified and potential risks of COVID-19 mRNA vaccine. The necessary information to ensure appropriate use of the product is included in the relevant sections of the SmPC. No additional measures for risk minimisation are considered necessary by the MAA at this time. The proposed minimisation measures are summarised in the table below for each safety concern.

**Table 29. Description of Routine Risk Minimisation Measures by Safety Concern**

Safety Concern	Routine risk minimisation activities
<b>Important Identified Risk</b>	
Anaphylaxis	<u>Routine risk communication:</u> SmPC section 4.4 Special warnings and precautions for use and section 4.8 Undesirable effects. <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.
<b>Important Potential Risk</b>	
Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)	<u>Routine risk communication:</u> None. <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.
<b>Missing Information</b>	
Use in pregnancy and while breast feeding	<u>Routine risk communication:</u> SmPC section 4.6 Fertility, pregnancy and lactation PL section 2. What you need to know before you receive Comirnaty <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.

**Table 29. Description of Routine Risk Minimisation Measures by Safety Concern**

<p>Use in immunocompromised patients</p>	<p><u>Routine risk communication:</u> SmPC section 4.4 Special warnings and precautions for use and section 5.1 Pharmacodynamic properties. <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.</p>
<p>Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)</p>	<p><u>Routine risk communication:</u> SmPC section 5.1 Pharmacodynamic properties. <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.</p>
<p>Use in patients with autoimmune or inflammatory disorders</p>	<p><u>Routine risk communication:</u> None. <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> <u>None.</u></p>
<p>Interaction with other vaccines</p>	<p><u>Routine risk communication:</u> SmPC section 4.5 Interaction with other medicinal products and other forms of interaction <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.</p>
<p>Long term safety data</p>	<p><u>Routine risk communication:</u> None. <u>Routine risk minimisation activities recommending specific clinical measures to address the risk:</u> None. <u>Other routine risk minimisation measures beyond the Product Information:</u> None.</p>

## V.2. Additional Risk Minimisation Measures Risk Minimisation Measures

Routine risk minimisation activities as described in [Part V.1](#) are sufficient to manage the safety concerns of the medicinal product.

## V.3. Summary of Risk Minimisation Measures

**Table 30. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern**

Safety Concern	Risk Minimisation Measures	Pharmacovigilance Activities
Anaphylaxis	<p><u>Routine risk minimisation measures:</u> SmPC sections 4.4. and 4.8.</p> <p><u>Additional risk minimisation measures:</u> <u>None.</u></p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> DCA is intended to facilitate the capture of clinical details about potential anaphylactic reactions in individuals who have received the COVID-19 mRNA vaccine (cross. Ref with <a href="#">Section III.1</a>).</p> <p><u>Additional pharmacovigilance activities:</u> Studies (Final CSR Due Date):</p> <ul style="list-style-type: none"> <li>• C4591001 (31-Aug-2023)</li> <li>• C4591010 (31-Mar-2024)</li> <li>• C4591011 (31-Dec-2023)</li> <li>• C4591012 (31-Dec-2023)</li> <li>• ACCESS/VAC4EU (31-Jan-2024).</li> </ul>
Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)	<p><u>Routine risk minimisation measures:</u> None.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> DCA is intended to facilitate the capture of clinical details about the nature and severity of COVID-19 illness in individuals who have received the COVID-19 mRNA vaccine and is anticipated to provide insight into potential cases of vaccine lack of effect or VAED (cross. Ref with <a href="#">Section III.1</a>).</p> <p><u>Additional pharmacovigilance activities:</u> Studies (Final CSR Due Date)</p> <ul style="list-style-type: none"> <li>• C4591001 (31-Aug-2023)</li> <li>• C4591011 (31-Dec-2023)</li> <li>• C4591012 (31-Dec-2023)</li> <li>• ACCESS/VAC4EU (31-Jan-2024).</li> </ul>

**Table 30. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern**

Safety Concern	Risk Minimisation Measures	Pharmacovigilance Activities
Use in pregnancy and while breast feeding	<p><u>Routine risk minimisation measures:</u> SmPC section 4.6; PL section 2.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> None.</p> <p><u>Additional pharmacovigilance activities:</u> Studies (Final CSR Due Date)</p> <ul style="list-style-type: none"> <li>• C4591010 <sup>a</sup>(31-Mar-2024)</li> <li>• C4591011 <sup>a</sup>(31-Dec-2023)</li> <li>• C4591015 (30-Apr-2023)</li> <li>• ACCESS/VAC4EU <sup>a</sup> (31-Jan-2024).</li> </ul>
Use in immunocompromised patients	<p><u>Routine risk minimisation measures:</u> SmPC sections 4.4 and 5.1.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> None.</p> <p><u>Additional pharmacovigilance activities:</u> Studies (Final CSR or IA Due Date)</p> <ul style="list-style-type: none"> <li>• BNT162-01 Cohort 13 (IA: 30-Sep-2021, CSR: 31-Dec-2022)</li> <li>• C4591018 (IA: 31-Dec-2021)</li> <li>• C4591011 (31-Dec-2023)</li> <li>• C4591012 (31-Dec-2023)</li> <li>• ACCESS/VAC4EU (31-Jan-2024).</li> </ul>
Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)	<p><u>Routine risk minimisation measures:</u> SmPC section 5.1.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> None.</p> <p><u>Additional pharmacovigilance activities:</u> Studies (Final CSR Due Date submission)</p> <ul style="list-style-type: none"> <li>• C4591001 subset (31-Aug-2023)</li> <li>• C4591011 (31-Dec-2023)</li> <li>• C4591012 (31-Dec-2023)</li> <li>• ACCESS/VAC4EU (31-Jan-2024)</li> <li>• Safety and immunogenicity in high risk adults (31-Dec-2022).</li> </ul>
Use in patients with autoimmune or inflammatory disorders	<p><u>Routine risk minimisation measures:</u> None.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> None.</p> <p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591011 (31-Dec-2023)</li> <li>• C4591012 (31-Dec-2023)</li> <li>• C4591018 (31-Dec-2021)</li> <li>• ACCESS/VAC4EU (31-Jan-2024).</li> </ul>



**Table 30. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern**

Safety Concern	Risk Minimisation Measures	Pharmacovigilance Activities
Interaction with other vaccines	<p><u>Routine risk minimisation measures:</u> SmPC section 4.5.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> None.</p> <p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• Co-administration study with seasonal influenza vaccine (31-Dec-2022).</li> </ul>
Long term safety data	<p><u>Routine risk minimisation measures:</u> None.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>	<p><u>Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:</u> None.</p> <p><u>Additional pharmacovigilance activities:</u> Studies (Final CSR Due Date or IA CSR submission)</p> <ul style="list-style-type: none"> <li>• C4591001 (31-Aug-2023)</li> <li>• C4591010 (31-Mar-2024)</li> <li>• C4591011 (31-Dec-2023)</li> <li>• C4591012 (31-Dec-2023)</li> <li>• ACCESS/VAC4EU (31-Jan-2024).</li> </ul>

a. Please note that studies C4591010, C4591011 and ACCESS/VAC4EU address only “Use in pregnancy”.

## **PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN**

### **Summary of risk management plan for Comirnaty.**

This is a summary of the risk management plan (RMP) for Comirnaty. The RMP details important risks of Comirnaty, how these risks can be minimised, and how more information will be obtained about Comirnaty's risks and uncertainties (missing information).

Comirnaty's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Comirnaty should be used.

This summary of the RMP for Comirnaty should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Comirnaty's RMP.

### **I. The Medicine and What It Is Used For**

Comirnaty is a vaccine for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. (see SmPC for the full indication). It contains nucleoside-modified messenger RNA encapsulated in lipid nanoparticles as the active substance and it is given intramuscularly.

Further information about the evaluation of Comirnaty's benefits can be found in Comirnaty's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage [www.ema.europa.eu/en/medicines/human/EPAR/comirnaty](http://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty).

### **II. Risks Associated With the Medicine and Activities to Minimise or Further Characterise the Risks**

Important risks of Comirnaty, together with measures to minimise such risks and the proposed studies for learning more about Comirnaty's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse events is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Comirnaty is not yet available, it is listed under ‘missing information’ below.

## II.A List of Important Risks and Missing Information

Important risks of Comirnaty are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Comirnaty. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

**Table 31. List of Important Risks and Missing Information**

Important identified risks	Anaphylaxis
Important potential risks	Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)
Missing information	Use in pregnancy and while breast feeding
	Use in immunocompromised patients
	Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)
	Use in patients with autoimmune or inflammatory disorders
	Interaction with other vaccines
	Long term safety data

## II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference.

**Table 32. Important Identified Risk: Anaphylaxis**

Evidence for linking the risk to the medicine	Events of anaphylaxis have been reported.
Risk factors and risk groups	Known allergy to the vaccine or its ingredients.
Risk minimisation measures	<u>Routine risk minimisation measures</u> SmPC sections 4.4. and 4.8. <u>Additional risk minimisation measures:</u> None.

**Table 32. Important Identified Risk: Anaphylaxis**

Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591001</li> <li>• C4591010</li> <li>• C4591011</li> <li>• C4591012</li> <li>• ACCESS/VAC4EU</li> </ul> <p>See section I.I.C of this summary for an overview of the post-authorisation development plan.</p>
---	---

**Table 33. Important Potential Risk: Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)**

Evidence for linking the risk to the medicine	<p>VAED is considered a potential risk because it has not been seen in human studies with this or other COVID-19 vaccines being studied. It has not been seen in vaccine studies in animal models of the SARS-CoV-2 virus either. However, in selected vaccine studies in animal models as well as in some laboratory studies in animal cells infected with 2 other related coronaviruses (SARS-CoV-1 and MERS-CoV), abnormalities in immune responses or cellular responses indicative of VAED were observed. Because of this, VAED is considered a potential risk. In the past there have been other examples of particularly respiratory viruses where VAED has been observed. For example, some children who received an inactivated respiratory syncytial virus vaccine (a different type of virus), had worse signs of disease when they were subsequently infected with respiratory syncytial virus.</p> <p>VAED is thought to occur by several mechanisms where the immune response is not fully protective and actually either causes the body to have an inflammatory reaction due to the type of immune response with specific types of T-cells, or the body does not produce enough strong antibodies to prevent SARS-CoV-2 infection of cells or produces weak antibodies that actually bind to the virus and help it to enter cells more easily, leading to worse signs of disease.</p>
Risk factors and risk groups	It is thought that the potential risk of VAED may be increased in individuals producing a weak antibody response or in individuals with decreasing immunity over time.
Risk minimisation measures	<p><u>Routine risk minimisation measures</u> None.</p> <p><u>Additional risk minimisation measures:</u> None.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591001</li> <li>• C4591011</li> <li>• C4591012</li> <li>• ACCESS/VAC4EU</li> </ul> <p>See section I.I.C of this summary for an overview of the post-authorisation development plan.</p>

**Table 34. Missing Information: Use in pregnancy and while breast feeding**

Risk minimisation measures	<p><u>Routine risk minimisation measures:</u> SmPC section 4.6; PL section 2.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591010 <sup>a</sup></li> <li>• C4591011 <sup>a</sup></li> <li>• C4591015</li> <li>• ACCESS/VAC4EU</li> </ul> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>

a. Please note that studies C4591010, C4591011 and ACCESS/VAC4EU address only “Use in pregnancy”.

**Table 35. Missing Information: Use in immunocompromised patients**

Risk minimisation measures	<p><u>Routine risk minimisation measures:</u> SmPC sections 4.4 and 5.1.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• BNT162-01 cohort 13</li> <li>• C4591018</li> <li>• C4591011</li> <li>• C4501012</li> <li>• ACCESS/VAC4EU.</li> </ul> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>

**Table 36. Missing Information: Use in frail patients with co-morbidities (e.g. chronic obstructive pulmonary disease (COPD), diabetes, chronic neurological disease, cardiovascular disorders)**

Risk minimisation measures	<p><u>Routine risk minimisation measures:</u> SmPC section 5.1.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591001 subset</li> <li>• C4591011</li> <li>• C4501012</li> <li>• ACCESS/VAC4EU</li> <li>• Safety and immunogenicity in high risk adults</li> </ul> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>

**Table 37. Missing Information: Use in patients with autoimmune or inflammatory disorders**

Risk minimisation measures	<p><u>Routine risk minimisation measures:</u> None.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591011</li> <li>• C4501012</li> <li>• ACCESS/VAC4EU</li> <li>• C4591018</li> </ul> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>

**Table 38. Missing Information: Interaction with other vaccines**

Risk minimisation measures	<p><u>Routine risk minimisation measures:</u> SmPC section 4.5.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• Co-administration study with seasonal influenza vaccine</li> </ul> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>

**Table 39. Missing Information: Long term safety data**

Risk minimisation measures	<p><u>Routine risk minimisation measures:</u> None.</p> <p><u>Additional risk minimisation measures:</u> No risk minimisation measures.</p>
Additional pharmacovigilance activities	<p><u>Additional pharmacovigilance activities:</u></p> <ul style="list-style-type: none"> <li>• C4591001</li> <li>• C4591010</li> <li>• C4591011</li> <li>• C4591012</li> <li>• ACCESS/VAC4EU</li> </ul> <p>See section II.C of this summary for an overview of the post-authorisation development plan.</p>

## II.C Post-Authorisation Development Plan

### II.C.1 Studies which are Conditions of the Marketing Authorisation

Study	Purpose of the study
C4591001	<p>The objective of the study is to evaluate the safety, tolerability, immunogenicity and efficacy of COVID-19 mRNA vaccine.</p> <p>An unfavorable imbalance between the vaccine and control groups in the frequency of COVID-19, in particular for severe COVID-19, may suggest the occurrence of vaccine associated enhanced disease. Surveillance is planned for 2 years following Dose 2.</p>

### II.C.2 Other Studies in Post-Authorisation Development Plan

Study	Purpose of the study
C4591011	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in a cohort of people within the Department of Defense Healthcare System.
C4591012	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine.
C4591010	Assessment of occurrence of safety events in real-world use of COVID-19 mRNA vaccine.
C4591015	<p>Planned clinical study to assess safety and immunogenicity in pregnant women who receive COVID-19 mRNA vaccine.</p> <p>Safety and immunogenicity of COVID-19 mRNA vaccine in pregnant women.</p>
C4591014	Estimate the effectiveness of 2 doses of COVID-19 mRNA vaccine against potential COVID-19 illness requiring admission to the ED or hospital where SARS-CoV-2 is identified.
BNT162-01 Cohort 13	To assess potentially protective immune responses in immunocompromised adults.
C4591018	Safety, immunogenicity over 12 months; description of COVID-19 cases; rheumatoid arthritis activity by Clinical Disease Activity Index; N-antigen antibodies for detection of asymptomatic infection.
Safety and immunogenicity in high risk adults	Safety, immunogenicity over 12 months in frail elderly, immunocompromised, autoimmune and other high-risk individuals; description of COVID-19 cases; N-antigen antibodies for detection of asymptomatic infection.
ACCESS/VAC4EU	Assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine.
Co-administration study with seasonal influenza vaccine	Safety and immunogenicity of BNT162b2 and quadrivalent seasonal influenza vaccine when administered separately or concomitantly.

## **PART VII. ANNEXES TO THE RISK MANAGEMENT PLAN**

### **Table of contents**

Annex 2 – Tabulated summary of planned, on-going, and completed pharmacovigilance study programme

Annex 3 – Protocols for proposed, on-going, and completed studies in the pharmacovigilance plan

Annex 4 – Specific Adverse Drug Reaction Follow- Up Forms

Annex 5 – Protocols for proposed and on-going studies in RMP Part IV

Annex 6 – Details of Proposed Additional Risk Minimisation Activities (if applicable)

Annex 7 – Other Supporting Data (Including Referenced Material)

Annex 8 – Summary of Changes to the Risk Management Plan over Time



## REFERENCES

- 1 [Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382\(8\):727-33.](#)
- 2 [World Health Organization. 2020. Coronavirus Disease 2019 \(COVID-19\) Situation Report – 11.](#)
- 3 [Worldometers.info. Reported Cases and Deaths by Country, Territory, or Conveyance. 09 November, 2020. Dover, Delaware, U.S.A.   
https://www.worldometers.info/coronavirus/#countries. Data accessed on 09 November, 2020](#)
- 4 [Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff \(Millwood\) 2020;39\(7\):1253-62.](#)
- 5 [Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985.](#)
- 6 [Hur K, Price CPE, Gray EL, et al. Factors associated with intubation and prolonged intubation in hospitalized patients with COVID-19. \[published correction appears in Otolaryngol Head Neck Surg. 2020 Jul;163\(1\):NP1\]. Otolaryngol Head Neck Surg 2020;163\(1\):170-8.](#)
- 7 [Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open 2020;3\(6\):e2012270.](#)
- 8 [ECDC. COVID-19 Surveillance report. Week 31, 2020. 7 August 2020. “5 TESSy data quality”.   
https://COVID19-surveillance-report.ecdc.europa.eu](#)
- 9 [European Centre for Disease Prevention and Control. Coronavirus disease 2019 \(COVID-19\) in the EU/EEA and the UK—eleventh update: resurgence of cases. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2020.   
https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-20200810.pdf](#)
- 10 [ECDC. COVID-19 Surveillance report. Week 31, 2020. 7 August 2020. “2.2 Age-sex pyramids”.   
https://COVID19-surveillance-report.ecdc.europa.eu](#)
- 11 [Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69\(24\):759-65.](#)

- 12 [Boehmer TK, DeVies J, Caruso E, et al. Changing Age Distribution of the COVID-19 Pandemic — United States, May–August 2020. MMWR Morb Mortal Wkly Rep 2020;69\(39\):1404-9.](#)
- 13 <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html>
- 14 [Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395\(10239\):1763-70.](#)
- 15 [Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and mortality among black patients and white patients with COVID-19. N Engl J Med 2020;382\(26\):2534-43.](#)
- 16 [Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.](#)
- 17 [Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 2020;369:m1996.](#)
- 18 [Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020;323\(20\):2052-9.](#)
- 19 [Holmes L Jr, Enwere M, Williams J, et al. Black-white risk differentials in COVID-19 \(SARS-COV2\) transmission, mortality and case fatality in the United States: translational epidemiologic perspective and challenges. Int J Environ Res Public Health 2020;17\(12\):4322.](#)
- 20 [Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20\(6\):669-77.](#)
- 21 [Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 \(COVID-19\): A Review. JAMA 2020;324\(8\):782-93.](#)
- 22 [Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 - Georgia, March 2020. MMWR Morb Mortal Wkly Rep 2020;69\(18\):545-50.](#)
- 23 [Nowak B, Szymański P, Pańkowski I, et al. Clinical characteristics and short-term outcomes of patients with coronavirus disease 2019: a retrospective single-center experience of a designated hospital in Poland. Pol Arch Intern Med 2020;130\(5\):407-11.](#)

- 24 Iaccarino, G, Grassi G, Borghi C, et al. Age and multimorbidity predict death among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. *Hypertension* 2020;76(2):366-72.
- 25 Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. *Vaccine* 2020;38(31):4783-4791.
- 26 Singh DK, Ganatra SR, Singh B, et al. SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species. *bioRxiv* 2020:06.05.136481.
- 27 World Health Organization. Annex 1. WHO guidelines on nonclinical evaluation of vaccines. In: World Health Organization. WHO technical report series, no. 927. Geneva, Switzerland; World Health Organization; 2005:31-63.
- 28 Kozauer NA, Dunn WH, Unger EF, et al. CBER multi-discipline review of Onpattro. NDA 210922. 10 Aug 2018. NDA 210922 Patisiran Cross-Discipline Team Leader Review. (Center for Drug Evaluation and Research, Food and Drug Administration, [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2018/210922Orig1s000MultiR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000MultiR.pdf))
- 29 Sedic M, Senn JJ, Lynn A, et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. *Vet Pathol* 2018;55(2)(03):341-54.
- 30 Law B, Sturkenboom M. D2.3 priority list of adverse events of special interest: COVID-19. In: WP2 standards and tools. V2.0. 25-05-2020. Brighton Collaboration. Decatur, GA: Safety Platform for Emergency vACCines; 2020: 52 pages.
- 31 ACCESS Protocol Background rates of adverse events of special interest for monitoring COVID-19 vaccines, version 1.1, 21 Sep 2020. <https://vac4eu.org/covid-19-vaccine-monitoring/>
- 32 Shimabukuro T. Enhanced safety monitoring for COVID-19 vaccines in early phase vaccination. In: ACIP presentation. Atlanta, GA: National Center for Immunization & Respiratory Diseases; 2020: 21 pages.
- 33 Haynes BF, Corey L, Fernandes P, et al. Prospects for a safe COVID-19 vaccine. *Sci Transl Med* 2020;12(568):eabe0948.
- 34 Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. *Vaccine* 2001;20(Suppl 1):S27-31.
- 35 Graham BS. Rapid COVID-19 vaccine development. *Science* 2020;368(6494):945-6.

- <sup>36</sup> Munoz FM, Cramer JP, Dekker CL. Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. 19 October 2020. <https://brightoncollaboration.us/vaed/>
- <sup>37</sup> Sahin U, Muik A, Derhovanessian E, et al. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv 2020.07.17.20140533.
- <sup>38</sup> Vogel AB, Kanevsky I, Che Ye, et al. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv 2020.09.08.280818.

**Instructions for use:**

This Data Capture Aid (DCA) is intended to capture the available clinical details about the nature and severity of COVID-19 illness experienced, particularly in relation to potential cases of vaccine lack of effect or vaccine associated enhanced disease (VAED).

Select questions as needed to obtain any DCA-defined information described below that was not included in the initial report.

**AER/Manufacturer Report #:** \_\_\_\_\_

**Suspect product:** \_\_\_\_\_

**Reported event term prompting special follow-up activities:** \_\_\_\_\_

**AE onset date (dd-Mmm-yyyy):** \_\_\_\_\_

**Patient Age (e.g., 65 years):** \_\_\_\_\_

**Patient Gender:**  Male  Female  Not Stated

**Race:**  White  Black or African American  Native American  Alaska Native  Native Hawaiian  Asian  Other  
 Refused or Don't Know

**Ethnic Group:**  Hispanic/LatinX  Non-Hispanic/Non-LatinX

**Reporter Information**

Name of reporter completing this form (If other than addressee, provide contact information below):		
Phone Number:	Fax Number:	Email Address:

**1. Product information (Pfizer-BioNTech COVID-19 Vaccine)**

Dose	Date (dd-Mmm-yyyy)	Site of injection	Route	Batch/Lot number
<u>1<sup>st</sup></u> dose				
<u>2<sup>nd</sup></u> dose				

## Follow-up Questions

Please provide additional details on a separate page if needed and reference the question number.

**1. Does the patient have a positive test for SARS-CoV2?**

Unknown  No  Yes → If Yes, please provide details (and indicate if this is a new infection or a recurrence)  
 Details: (Please specify date of test and type of test – e.g., nasal swab reverse transcription–polymerase chain reaction (RT-PCR) test or nucleic acid amplification–based test (NAAT) or antigen test)

**2. Does the patient have SARS-CoV2 antibodies at diagnosis?**

Unknown  No  Yes → If Yes, please provide details  
 Details: (Please specify date of test, whether IgM /IgG or both and the titer if available)

**3. Was/Is the patient hospitalized?**

Unknown  No  Yes → If Yes, please provide details (e.g., duration of hospitalization)  
 Details:

**4. Was/Is the patient admitted to an Intensive Care Unit?**

Unknown  No  Yes → If Yes, please provide details (e.g., duration of hospitalization)  
 Details:

**5. Is the patient still hospitalized?**

Unknown  No  Yes → If Yes, please provide details (e.g., duration of hospitalization)  
 Details:

**6. If discharged, did the patient have SARS-CoV2 antibodies at hospital discharge?**

Unknown  No  Yes → If Yes, please provide details  
 Details: (Please specify date of test, whether IgM /IgG or both and the titer if available)

**7. Did the patient display clinical signs at rest indicative of severe systemic illness?**

Unknown  No  Yes → If Yes, please provide details (e.g., Fever, RR  $\geq$ 30 breaths per minute, HR  $\geq$ 125 beats per minute, use of vasopressors to maintain BP, SpO<sub>2</sub>  $\leq$ 93% on room air, PaO<sub>2</sub>/FiO<sub>2</sub> <300 mm Hg?)  
 Details:

**8. Did the patient require supplemental oxygen (including high flow or ECMO) or receive mechanical ventilation?**

Unknown  No  Yes → If Yes, please provide details (e.g., oxygen requirements, pulse oximetry results)  
 Details:

**9. Please provide information on any new or worsened symptoms/signs during the COVID-19 illness experienced (including date of onset/worsening)**

**Multiorgan failure**  Unknown  No  Yes → If Yes, please indicate which organ systems were affected and provide information on the applicable systems below

Respiratory  Cardiovascular  Gastrointestinal/Hepatic  Vascular  Renal  Neurological  Hematological  Dermatological  
 Other

**Respiratory**  Unknown  No  Yes → *If Yes, please provide details*  
**Dyspnea**  Unknown  No  Yes → *If Yes, please provide details*  
**Tachypnea**  Unknown  No  Yes → *If Yes, please provide details*  
**Hypoxemia**  Unknown  No  Yes → *If Yes, please provide details*  
**COVID-pneumonia**  Unknown  No  Yes → *If Yes, please provide details*  
**Respiratory failure**  Unknown  No  Yes → *If Yes, please provide details*  
**Acute Respiratory Distress Syndrome (ARDS)**  Unknown  No  Yes → *If Yes, please provide details*  
**Other**  Unknown  No  Yes → *If Yes, please provide details*

*Details:*

**Cardiovascular**  Unknown  No  Yes → *If Yes, please provide details*  
**Heart failure**  Unknown  No  Yes → *If Yes, please provide details*  
**Cardiogenic shock**  Unknown  No  Yes → *If Yes, please provide details*  
**Acute myocardial infarction**  Unknown  No  Yes → *If Yes, please provide details*  
**Arrhythmia**  Unknown  No  Yes → *If Yes, please provide details*  
**Myocarditis**  Unknown  No  Yes → *If Yes, please provide details*  
**Other**  Unknown  No  Yes → *If Yes, please provide details*

*Details:*

**Gastrointestinal/Hepatic**  Unknown  No  Yes → *If Yes, please provide details*  
**Vomiting**  Unknown  No  Yes → *If Yes, please provide details*  
**Diarrhea**  Unknown  No  Yes → *If Yes, please provide details*  
**Abdominal pain**  Unknown  No  Yes → *If Yes, please provide details*  
**Jaundice**  Unknown  No  Yes → *If Yes, please provide details*  
**Acute liver failure**  Unknown  No  Yes → *If Yes, please provide details*  
**Other**  Unknown  No  Yes → *If Yes, please provide details*

*Details:*

**Vascular**  Unknown  No  Yes → *If Yes, please provide details*  
**Deep vein thrombosis**  Unknown  No  Yes → *If Yes, please provide details*  
**Pulmonary embolism**  Unknown  No  Yes → *If Yes, please provide details*  
**Limb ischemia**  Unknown  No  Yes → *If Yes, please provide details*  
**Vasculitis**  Unknown  No  Yes → *If Yes, please provide details*  
**Other (in particular any other thromboembolic events)**  Unknown  No  Yes → *If Yes, please provide details*

*Details:*

**Renal**  Unknown  No  Yes → *If Yes, please provide details*  
**Acute kidney injury**  Unknown  No  Yes → *If Yes, please provide details*  
**Renal failure**  Unknown  No  Yes → *If Yes, please provide details*  
**Other**  Unknown  No  Yes → *If Yes, please provide details*

*Details:*

**Neurological**  Unknown  No  Yes → *If Yes, please provide details*  
**Altered consciousness**  Unknown  No  Yes → *If Yes, please provide details*

**Convulsions/seizures**  Unknown  No  Yes → If Yes, please provide details  
**Encephalopathy**  Unknown  No  Yes → If Yes, please provide details  
**Meningitis**  Unknown  No  Yes → If Yes, please provide details  
**Cerebrovascular accident**  Unknown  No  Yes → If Yes, please provide details and indicate if ischemic or hemorrhagic  
**Other**  Unknown  No  Yes → If Yes, please provide details

Details:

**Hematological**  Unknown  No  Yes → If Yes, please provide details  
**Thrombocytopenia**  Unknown  No  Yes → If Yes, please provide details (see also Q14)  
**Disseminated intravascular coagulation**  Unknown  No  Yes → If Yes, please provide details (see also Q14)  
**Other**  Unknown  No  Yes → If Yes, please provide details

Details:

**Dermatological**  Unknown  No  Yes → If Yes, please provide details  
**Chillblains**  Unknown  No  Yes → If Yes, please provide details  
**Erythema multiforme**  Unknown  No  Yes → If Yes, please provide details  
**Other**  Unknown  No  Yes → If Yes, please provide details

Details:

**OTHER** (e.g. multisystem inflammatory syndrome [MIS])  Unknown  No  Yes → If Yes, please provide details  
 Details:

#### 10. Did the patient receive any additional therapies for COVID-19?

Therapy	Date Started (dd-Mmm-yyyy)	Date Stopped (dd-Mmm-yyyy)	Dose/Any additional information
<input type="checkbox"/> Remdesivir			
<input type="checkbox"/> Hydroxychloroquine/chloroquine			
<input type="checkbox"/> Azithromycin			
<input type="checkbox"/> Corticosteroids			
<input type="checkbox"/> Other (Please Specify)			

#### 11. Did the event require the initiation of new medication or other treatment or procedure?

Unknown  No  Yes → If Yes, please provide details

Details:



**12. Patient's outcome with COVID-19:**

Recovering  Recovered  Not recovered  Unknown  Fatal, Date (dd-Mmm-yyyy): .....

If outcome is fatal, was an autopsy performed?  Unknown  No  Yes → If Yes, please provide autopsy findings

Details:

**13. How many days from the SARS-CoV2 diagnosis did it take before the SARS-CoV2 antigen test became negative?****14. Were any of the following laboratory tests or diagnostic studies performed? Please specify laboratory data with units, date of test, and reference ranges; and please provide printouts and photographs if available:**

Laboratory Test or Diagnostic Studies	Date Performed (dd-Mmm-yyyy)	Results with units, if applicable	Reference Ranges, if applicable (or please state if abnormal or elevated/reduced)
<input type="checkbox"/> Test for SARS-CoV-2 by PCR, or other commercial or public health assay			
<input type="checkbox"/> Imaging for COVID-Pneumonia (e.g. CXR, CT)			
<input type="checkbox"/> Other radiological investigations (e.g. MRI, angiogram, V/Q scan)			
<input type="checkbox"/> Imaging for thrombo-embolic events (e.g. doppler or CT)			
<input type="checkbox"/> Hematology (e.g. leucocyte count [including neutrophil and lymphocyte counts], hemoglobin, platelet count, coagulation parameters [PT, PTT, D-Dimer, INR], fibrinogen, B and T cell function assays)			
<input type="checkbox"/> Clinical chemistry (e.g. serum creatinine, glomerular filtration rate [GFR], liver enzymes, bilirubin, albumin, B-type natriuretic peptide [BNP], troponin)			
<input type="checkbox"/> Inflammatory markers (e.g. CRP, ESR, procalcitonin, ferritin, LDH, cytokines [including IL-6])			
<input type="checkbox"/> Urinalysis			
<input type="checkbox"/> Evidence of hypoxemia (e.g. PaO <sub>2</sub> /FiO <sub>2</sub> [P/F ratio], SpO <sub>2</sub> /FiO <sub>2</sub> [S/F ratio]), hypercapnia (PaCO <sub>2</sub> ) or acidosis (pH)			
<input type="checkbox"/> Other relevant tests (please specify): _____			

## Past Medical History Questions

*Please provide additional details on a separate page if needed and reference the question number.*

**15. Does the patient have a history of any of the following?**

- Hypertension  
 Diabetes  
 Heart Disease *(please specify)*  
 Lung Disease *(please specify)*  
 Liver disease *(please specify)*  
 Kidney disease *(please specify)*  
 Cancer *(please specify)*  
 Immunosuppressive disorder *(please specify)*  
 Obesity  
 Other *(please specify)*

*Details:*

**16. Is the patient a smoker/former smoker?**

- Current Smoker    Former smoker    No

*Details:*

**17. Was the patient taking any medications routinely prior to the event being reported?**

- Unknown    No    Yes → *If Yes, please provide details*

*Details:*

**18. Have any pre-existing diseases worsened during the SARS-CoV2 infection (please specify)**

- Unknown    No    Yes → *If Yes, please provide details*

*Details:*

**19. Has the patient been treated with immunomodulating or immunosuppressing medications or received any other vaccines around the time of COVID-19 vaccination?**

- Unknown    No    Yes → *If Yes, please provide details*

*Details:*

### Revision History

Revision	Effective Date	Summary of Revisions
1.0	07-Dec-2020	New DCA